UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended: ~~March~~June 3130, 2017

[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from __________ to ___________

Commission File Number: 001-28911

CANNABIS SCIENCE, INC.

(Exact name of registrant as specified in its charter)

Nevada	91-1869677
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

19800 MacArthur Blvd., Suite 300, Irvine, California	92612
(Address of principal executive offices)	(Zip Code)


(888) 263-0832
(Registrant’ s telephone number, including area code)


(Former name, former address and former fiscal year, if changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. [X] Yes [ ] No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). [X] Yes [ ] No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a not-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer [ ] Accelerated filer [ ]

Non-accelerated filer [ ] Smaller reporting company [X]

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). [ ] Yes [X] No

Number of common shares issued and outstanding at ~~March~~June 3130, 2017: 2,~~443~~461,355,296

Number of common shares outstanding at ~~July~~ 14August 18, 2017: 2,~~466~~521,805,296

Number of Class A common shares outstanding at ~~July~~August 1418, 2017: 0

CANNABIS SCIENCE, INC.

FORM 10-Q

For the Period Ended ~~March~~June 3130, 2017

TABLE OF CONTENTS

	Page
PART I FINANCIAL INFORMATION		3
Item 1. Consolidated Financial Statements		3
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations		4
Item 3. Quantitative and Qualitative Disclosures about Market Risk		1011
Item 4. Controls and Procedures		11
PART II OTHER INFORMATION		11
Item 1. The Business		11
Item 1A. Risk Factors		1211
Item 2 Legal Proceedings		1314
Item 3. Unregistered Sales of Equity Securities and Use of Proceeds		14
Item 4. Defaults Upon Senior Securities		1415
Item 5. Mine Safety Disclosures.		1415
Item 6. Other Information		1415
Item 7. Exhibits and Certifications		1516

PART I FINANCIAL INFORMATION.

ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS

CANNABIS SCIENCE, INC.

		Page No.
Consolidated Balance Sheets as of March 31, 2017 and December 31, 2016…		F-1
Consolidated Balance Sheets as of June 30, 2017 and December 31, 2016…		F-1
Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the three months ended March 31, 2017 and 2016…		F-2
Consolidated Statements of Operations and Other Comprehensive Income (Loss) for the three and six months ended June 30, 2017 and 2016…		F-2
Consolidated Statements of Cash Flows for the three months ended March 31, 2017 and 2016…		F-3
Consolidated Statements of Cash Flows for the six months ended June 30, 2017 and 2016…		F-3
Consolidated Statements of Stockholders’ Deficit for the three months ended March 31, 2017		F-4
Consolidated Statements of Stockholders’ Deficit for the six months ended June 30, 2017		F-4
Notes to Consolidated Financial Statements…		F-5

CANNABIS SCIENCE, INC.
CONSOLIDATED BALANCE SHEETS
March 31, 2017 and December 31, 2016
June 30, 2017 and December 31, 2016
	March 31, 2017			December 31, 2016
	June 30, 2017			December 31, 2016
	(UNAUDITED)
	$			$
ASSETS
Current Assets
Cash		~~316~~321,~~591~~688			332,888
Other receivables		1517,~~520~~779			36,001
Prepaid expenses and deposits held with RMS (Note 11)		~~275~~478,~~744~~223			808,514
Inventory		~~103~~125,~~868~~009			102,993
Total current assets		~~711~~942,~~723~~699			1,280,396
Equipment and Greenhouse, net (Note 7)		~~330~~326,~~729~~966			—
Property Farming Rights (Note 8)		~~804~~1,~~492~~049,188			751,726
Equity method investee (Note 9)		~~325~~221,~~277~~633			272,644
Intangibles, net of accumulated amortization (Note 10)		~~161~~150,~~250~~500			172,000
TOTAL ASSETS		2,~~333~~690,~~471~~986			2,476,766
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities
Accounts payable		~~839~~812,~~903~~501			856,269
Accrued expenses, primarily management fees (Note 4)		1,~~062~~186,~~336~~845			884,465
Advances from related parties (Note 4)		~~572~~615,~~785~~515			538,425
Management bonuses		300,000			300,000
Notes payable to stockholders (Note 5)		1,~~590~~674,~~715~~685			1,506,745
Notes payable (Note 5)		~~396~~639,~~303~~343			177,698
Total current liabilities and total liabilities		45,~~762~~228,~~042~~889			4,263,602
Stockholders’ Deficit
Series A Preferred stock, $0.001 par value, 1,000,000 shares
authorized, 1,000,000 shares issued and outstanding at
March 31, 2017 and December 31, 2016		1,000			1,000
June 30, 2017 and December 31, 2016		1,000			1,000
Common stock, $.001 par value, 3,000,000,000 shares authorized,
2,443,355,296 issued and outstanding as of March 31,2017 and
2,461,855,296 issued and outstanding as of June 30,2017 and
2,350,355,296 at December 31, 2016		2,~~443~~461,~~356~~856			2,350,356
Common stock, Class A, $.001 par value, 100,000,000 shares
authorized, 0 issued and outstanding as of March 31, 2017 and December 31, 2016		—			—
authorized, 0 issued and outstanding as of June 30, 2017 and
Prepaid consulting		(3,759,810	)		(1,705,659	)
December 31, 2016		—			—
Common Stock receivable		(2,680,000	)		(655,000	)
Prepaid consulting		(3,507,316	)		(1,705,659	)
Additional paid-in capital		144,292,020			136,963,520
Common Stock receivable		(2,152,520	)		(655,000	)
Accumulated deficit		(142,163,656	)		(138,137,771	)
Additional paid-in capital		146,040,120			136,963,520
Cumulative exchange translation		(15,980	)		(11,495	)
Accumulated deficit		(144,822,153	)		(138,137,771	)
Equity attributable to common shareholders		(1,883,070	)		(1,195,049	)
Cumulative exchange translation		(12,858	)		(11,495	)
Non-Controlling interest		(545,501	)		(591,787	)
Equity attributable to common shareholders		(1,991,871	)		(1,195,049	)
Total stockholders' deficit		(2,428,571	)		(1,786,836	)
Non-Controlling interest		(546,032	)		(591,787	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		2,333,471			2,476,766
Total stockholders' deficit		(2,537,903	)		(1,786,836	)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT		2,690,986			2,476,766

The accompanying notes are an integral part of these consolidated financial statements.

F-1

CANNABIS SCIENCE, INC. CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS) FOR THE THREE AND SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2017 and 2016

(UNAUDITED)

	For the three months						For the six months
	ended March 31,
	ended June 30,						ended June 30,
	2017			2016			2017			2016
	$			$			$			$
REVENUE		~~3,733~~252			2,~~925~~862			3,985			5,787
Cost of Goods Sold		~~1,921~~141			~~1,598~~604			2,062			2,202
Gross Profit		~~1,812~~111			12,~~327~~258			1,923			3,585
Operating Expenses
Investor relations		20119,~~700~~411			~~157~~61,~~000~~350			140,111			218,350
Professional Fees		82185,~~374~~883			81113,~~690~~427			275,089			195,117
Net loss on settlement of liabilities		—			~~588,645~~—			—			588,645
Depreciation and Amortization		1014,~~814~~513			19,~~285~~284			25,327			38,569
Research and Development		~~216~~168,~~943~~889			~~163~~95,~~000~~537			385,832			258,537
General and administrative		31,~~400~~463,~~505~~149			21,~~391~~389,~~689~~479			5,132,856			3,781,168
Total operating expenses		31,~~731~~951,~~336~~845			31,~~401~~679,~~309~~077			5,959,215			5,080,386
Net Operating Loss		(31,~~729~~951,~~524~~734	)		(31,~~399~~676,~~982~~819	)		(5,957,292	)		(5,076,801	)
Other income (expense)
Interest expense, net		(~~302~~327,~~575~~010	)		(35867	)		(629,585	)		(902	)
Unrealized gain on equity investee		52,500			69,000
Unrealized (loss) on equity investee		(104,250	)		(69,000	)		(51,750	)		—
Total other income (expense)		(~~250~~431,~~075~~260	)		68(69,~~965~~867	)		(681,335	)		(902	)
Net Loss		(32,~~979~~382,~~599~~994	)		(31,~~331~~746,~~017~~686	)		(6,638,627	)		(5,077,703	)
Net (Income) loss attributable to non-controlling interest		~~(46,286~~778	)		4038,~~045~~368			(45,755	)		78,413
Net loss attributable to common shareholders		(42,~~025~~382,~~885~~216	)		(31,~~290~~708,~~972~~318	)		(6,684,382	)		(4,999,290	)
Other Comprehensive Income (Loss)
Foreign exchange translation adjustment		(~~4,485~~745	)		(2,~~096~~689	)		(1,363	)		593
Total other comprehensive income (Loss)		(~~4,485~~745	)		(2,~~096~~689	)		(1,363	)		593
Comprehensive loss attributable to Cannabis Science, Inc.		(42,~~030~~382,~~370~~961	)		(31,~~293~~705,~~068~~629	)		(6,685,745	)		(4,998,697	)
Net loss per common share:
Basic and diluted	$	(0.00	)	$	(0.00	)	$	(0.00	)	$	(0.00	)
Weighted average number of common shares outstanding		2,~~389~~456,~~710~~410,~~852~~241			1,~~680~~894,~~393~~641,~~758~~010			2,423,244,799			1,787,517,384
The accompanying notes are an integral part of these consolidated financial statements.

F-2

CANNABIS SCIENCE, INC. CONSOLIDATED STATEMENTS OF CASH FLOWS FOR THE ~~THREE~~SIX MONTHS ENDED ~~MARCH~~JUNE 3130, 2017 and 2016 (UNAUDITED)

	March 31, 2017			March 31, 2016
	June 30, 2017			June 30, 2016
	$			$
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss		(36,~~979~~638,~~599~~627	)		(35,~~331~~077,~~017~~703	)
Adjustments to reconcile net loss to net
cash used in operating activities:
Depreciation and amortization		21138,~~797~~865			1938,~~285~~569
Interest on debt conversion		~~302~~639,~~575~~244			—
Stock issued for services		23,~~712~~527,~~349~~443			12,~~738~~445,~~220~~759
Stock options issued for services		~~630~~1,259,000			~~437~~703,~~000~~500
(Gain) / Loss on settlement of liability		—			588,645
(Gain) / Loss on Equity Investee, Omnicanna Health Solutions, Inc.		~~(52~~51,~~500~~750	)		~~(69,000~~—	)
Changes in operating assets and liabilities: Other receivables		2018,~~481~~222			~~(16~~5,~~948~~950	)
Prepaid expenses and deposits held with RMS		~~529~~232,~~020~~791			(63,~~088~~896	)
Equity investee		(~~133~~739	)		(~~435~~204	)
Inventory		(~~875~~22,016	)		(6475,~~956~~927	)
Property farming rights		(60,000	)		—
Property farming rights and working capital		(313,500	)		—
Accounts payable		~~(16~~331,~~366~~232	)		67160,~~166~~618
Accrued expenses, primarily management fees		~~177~~302,~~871~~380			~~319~~596,~~000~~629
Loan receivable, related parties		3477,~~360~~090			2219,~~945~~141
NET CASH USED IN OPERATING ACTIVITIES		~~318~~(406,~~980~~524	)		(~~296~~591,~~183~~127	)
CASH FLOWS FROM INVESTING ACTIVITIES
Equipment and Greenhouse		(766	)		—
Advances receivable, related parties					17,516
Equipment and computers		(766	)		—
Greenhouse		(330,026	)		—
Property farming rights		—			(2550,000	)
CASH FLOWS PROVIDED BY (USED IN) INVESTING ACTIVITIES		(330,792	)		(2532,~~000~~484	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from common stock options exercised		—727,480			~~276~~591,~~500~~690
CASH FLOWS PROVIDED BY FINANCING ACTIVITIES		—727,480			~~276~~591,~~500~~690
Effect on exchange rate changes on cash		(41,~~485~~363	)		(2,~~096~~957	)
NET DECREASE IN CASH		(1611,~~297~~200	)		(4628,~~779~~964	)
CASH, BEGINNING OF PERIOD		332,888			61,971
CASH, END OF PERIOD		~~316~~321,~~591~~688			1533,~~192~~007
SUPPLEMENTAL CASH FLOW INFORMATION:
Common stock issued for services		—3,527,443			1,~~170~~408,~~982~~232
Common stock issued for settlement of debt		—			634,500
Common stock issued for options exercised		—1,259,000			12,~~338~~453,~~050~~500
Common stock issued for assets					181,350
Debt converted into common stock		—			45,855
Common stock subscription receivables		2,152,500			1,539,810
Accounts payable and expenses paid through advances from related parties		77,090			19,141

The accompanying notes are an integral part of these consolidated financial statements.

F-3

CANNABIS SCIENCE, INC.

CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ ~~EQUITY/~~ (DEFICIT)

FOR THE ~~THREE~~SIX MONTHS ENDED ~~March~~June 3130, 2017

	Common Shares		Par		Preferred Shares		Par		Additional Paid-In Capital		Prepaid Consulting			Accumulated Deficit			Common Stock Receivable			Cumulative Exchange Translation			Equity Attributable to Common Shareholders			Non-Controlling Interest			Totals
			$				$		$		$			$			$			$			$			$			$
Balance at December 31, 2016		2,350,355,296		2,350,356		1,000,000		1,000		136,963,520		(1,705,659	)		(138,137,771	)		(655,000	)		(11,495	)		(1,195,049	)		(591,787	)		(1,786,836	)
Common stock issued for services		5866,~~000~~500,000		5866,~~000~~500						45,~~708~~262,~~500~~600		(2,~~559~~334,~~000~~830	)					—						2,~~207~~994,~~500~~270						2,~~207~~994,~~500~~270
Common stock issued for stock option exercised		3545,000,000		3545,000						23,~~620~~439,000								(21,~~025~~497,~~000~~520	)					~~630~~1,~~000~~986,480						~~630~~1,~~000~~986,480
Amortization of shares issued for services												504,849												504,849						504,849
Intrinsic interest on convertible promissory notes										375,000														375,000						375,000
Net loss for the period															(4,025,885	)								(4,025,885	)		46,286			(3,979,599	)
Amortization of shares issued for services												533,173												533,173						533,173
Foreign exchange translation																					(4,485	)		(4,485	)					(4,485	)
Net loss for the period															(6,684,382	)								(6,684,382	)		45,755			(6,638,627	)
Balance at March 31, 2017		2,443,355,296		2,443,356		1,000,000		1,000		144,292,020		(3,759,810	)		(142,163,656	)		(2,680,000	)		(15,980	)		(1,883,070	)		(545,501	)		(2,428,571	)
Foreign exchange translation																					(1,363	)		(1,363	)					(1,363	)
Balance at June 30, 2017		2,461,855,296		2,461,856		1,000,000		1,000		146,040,120		(3,507,316	)		(144,822,153	)		(2,152,520	)		(12,858	)		(1,991,871	)		(546,032	)		(2,537,903	)

The accompanying notes are an integral part of these consolidated financial statements.

F-4

CANNABIS SCIENCE, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

~~March 31~~June 30, 2017

(UNAUDITED)

1. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

A. Organization and General Description of Business

Cannabis Science, Inc. (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.

On May 7, 2009 the Company common shares commenced trading under the new stock symbol OTC Pink: CBIS.

Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company formed two operating subsidiaries Cannabis Science BV and Cannabis Science International Holding BV in The Netherlands on May 10 th and May 6 th, 2013, respectively, to pursue business opportunities in Europe and worldwide. There are currently minimal operations in the subsidiaries. Agreements and business disclosures are in process.

On November 15, 2013, the Company submitted a patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD), anxiety, and sleep disorders.

B. Basis of Presentation

These consolidated financial statements and related notes are presented in accordance with accounting principles generally accepted in the United States, and are expressed in U.S. dollars. The Company’s fiscal year end is December 31.

Interim Financial Reporting

While the information presented in the accompanying interim consolidated financial statements is unaudited, it includes all adjustments, which are in the opinion of management, necessary to present fairly the financial position, results of operations and cash flows for the interim periods presented in accordance with general accepted accounting principles in the United States of America (“GAAP”). These interim financial statements follow the same accounting policies and methods of application as used in the December 31, 2016 audited financial statements of Cannabis Science, Inc. (the “Company”). All adjustments are of a normal, recurring nature. Interim financial statements and the notes thereto do not contain all of the disclosures normally found in the year-end audited financial statements and these Notes to Financial Statements are abbreviated and contain only certain disclosures related to the ~~three~~six-month periods ended ~~March 31~~June 30, 2017 and 2016. It is suggested that these interim financial statements be read in conjunction with the Company’s audited financial statements and related notes for the year ended December 31, 2016 included in our Form 10-K/A filed with the SEC on file no. 000-28911 ~~161631274~~171022778 ~~April~~August 1711, 2017. Operating results for the ~~three~~six months ended ~~March~~June 3130, 2017 are not necessarily indicative of the results that can be expected for the year ending December 31, 2017.

F-5

The following subsidiaries and controlling interests are included with the consolidated financial statements of the Company for the six ~~three~~ months ended ~~March~~June 3130, 2017:

In 2012, the Company formed Cannabis Science Europe GmbH (“CSE”) in which the Company own 90% to operate joint-venture operations with Dupetit Natural Products Ltd. The JV asset was sold to Endocan Corporation (formerly X-Change Corporation) on December 12, 2012. No operations had commenced at the time of sale of the JV asset. The Company has reignited the CSE by appointing Mr. Alfredo Dupetit on September 19, 2015 as president and chief executive officer of CSE. As recent as January 7, 2016, the Federal Health Ministry in Germany has presented “Cannabis as medicine”, a detailed draft bill that aims to modify the Drug Law and relax the strict measures that regulate the consumption of medical cannabis and, above all, become the main vehicle for everything relating to the plant and its medical users in the country. The Company has reinstated the development of cannabis products in February 2016 for medicinal uses in Germany.

On May 6, 2013, the Company formed Cannabis Science International Holdings B.V. and on May 10, 2013, the Company formed Cannabis Science B.V. for the purpose of wholly-owned operating subsidiaries for the Company’s European and world-wide operations. The Company has commenced some operating activities with cultivation in Spain and product development in 2014. Mario Lap, director of the Company and director and officer of Cannabis Science B.V. manages the day-to-day operations through his private companies MLS BV, MJR BV and Cannabis Agency BV, all are Netherlands registered companies.

On August 6, 2014, the Company signed a proposal letter with Michigan Green Technologies, LLC (“MGT”) to acquire an additional 30.1% equity in MGT and completed the transaction with the principals of MGT under the proposal letter on February 20, 2015 to effectively increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity, the Company issued 1,200,000 shares of common stock with a fair market value of $60,000 to the principals and shareholders of MGT.

On May 6, 2015, the Company announced the Assets acquisition of Equi-Pharm LLC, a USA manufacturer and distributor of specialty horse and pet grooming and topical applications. The acquisition incorporates an extensive expansion plan for Equi-Pharm including "Large Animal" such as horses, cattle, sheep and the like and "Small Animal" or "Pets" include cats, dogs, pet snakes and the like for medical and cosmetic products. As consideration for acquiring the Assets, which consist of Inventory, Trademark and brand names, and goodwill, the Company issued ten million (10,000,000) shares to the shareholders of Equi-Pharm and they agreed to change its company name. The acquisition was completed on November 16, 2015 and the Company has formed a new wholly owned subsidiary called Equi-Pharm LLC. in the state of Tennessee and started the operation of distributing of existing and new line of products.

On February 2, 2017, the Cannabis Science GmbH, a subsidiary 90% owned by the Company and 10% owned by Dupetit Natural Products GmbH, has entered a Share Purchase Agreement with Jinvator BioMed GmbH (Jinvator), a German corporation, for 74.9% of the total issued and outstanding shares of Jinvator for three hundred thousand Euros (€ 300,000) which has a US dollar equivalent of $320,430. Jinvator developed a prototype called nanoGold-Test which is based on nano-particle technology for the detection of HIV in the early stage of infection. Patent has been submitted and pending for approval. The acquisition is pending on verification of key information.

On May ~~March 27~~10, 2017, the Company ~~entered~~paid an€60,000, ~~agreement~~which tohas ~~acquire the Assets of AFA Research and Development,~~ a ~~California~~US ~~sole~~dollar ~~proprietorship~~equivalent of ~~Aja~~$65,214, ~~Fonseca~~to ~~Arnold in~~ the ~~research~~principal ~~and~~shareholder ~~development~~ of ~~products~~Jinvator BioMed ~~based~~GmbH ~~on cannabinoid~~ (~~CBD~~Jinvator) ~~and~~as ~~Tetrahydrocannabinol~~deposit ~~(THC)~~ for ~~patient care. As consideration for acquiring~~ the ~~Assets, which~~purchase ~~consist~~ of ~~brands,~~the pending trademarks, trade-names, designs, medicinal products and formulations, client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,00074.9% ~~The~~equity ~~completion~~interest ofin ~~assets acquisition is pending on verification of material information~~Jinvator. ~~In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.~~

~~For~~On March ~~other~~27, ~~accounting~~2017, ~~policies~~the ~~please~~Company ~~refer~~entered an agreement to acquire the ~~Company’s~~Assets of AFA Research and Development, a California sole proprietorship ~~Form~~of ~~10-K~~Aja ~~with~~Fonseca Arnold in the ~~SEC~~research and development of products based on ~~file~~cannabinoid no(CBD) and Tetrahydrocannabinol (THC) for patient care. ~~000~~As consideration for acquiring the Assets, which consist of brands, pending trademarks, trade-~~28911~~names, ~~161631274~~designs, ~~April~~medicinal products 17and formulations, ~~2017~~client base, computer hardware and software, intellectual properties, inventory, equipment, supplies, supplier’s information and contacts, contracted rights, properties, patents, and distribution rights for a total sum of $750,000. The completion of assets acquisition is pending on verification of material information. In addition, the Company engaged Aja Fonseca Arnold under a 5-year management agreement to continue the research and development of medicinal cannabis products for patient care with various ailments.

F-6

~~The Company qualifies as an “emerging growth company”~~For asother ~~defined~~accounting inpolicies ~~Section~~please ~~101~~refer ofto the ~~Jumpstart~~Company’s ~~our~~10-K/A ~~Business~~filed ~~Startups~~with ~~Act~~the ~~(“JOBS~~SEC ~~Act”)~~on asfile weno. ~~do not have more than $1,~~000~~,000,000 in~~-28911 ~~annual~~171022778 ~~gross revenue and did not have such amount as of December 31~~August 11, ~~2016, our last fiscal year. We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.~~2017

2The Company qualifies as an “emerging growth company” as defined in Section 101 of the Jumpstart our Business Startups Act (“JOBS Act”) as we do not have more than $1,000,000,000 in annual gross revenue and did not have such amount as of December 31, 2016, our last fiscal year. ~~GOING~~ ~~CONCERN~~We are electing to use the extended transition period for complying with new or revised accounting standards under Section 102(b)(1) of the JOBS Act.

The accompanying consolidated financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate the continuation of the Company as a going concern. The Company reported an accumulated deficit of $142,163,656 and had a stockholders’ deficit of $2~~,428,571~~. as GOING ~~of March 31, 2017.~~CONCERN

InThe accompanying ~~view~~consolidated offinancial ~~the~~statements ~~matters~~have ~~described,~~been ~~there~~prepared isin ~~substantial~~conformity ~~doubt~~with generally accepted accounting principles, aswhich tocontemplate the ~~Company's~~continuation ~~ability~~of tothe ~~continue~~Company as a going concern. The ~~without~~Company areported ~~significant~~an ~~infusion~~accumulated deficit of ~~capital. At March 31~~$144, ~~2017~~822,153 ~~the~~and ~~Company~~ had ~~insufficient~~a ~~operating~~stockholders’ ~~revenues~~deficit ~~and~~of ~~cash~~$2,537,903 ~~flow~~as toof ~~meet~~June ~~its~~30, ~~financial obligations~~2017. There can be no assurance that management will be successful in implementing its plans. The consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

~~We anticipate that we will have to raise additional capital~~In toview ~~fund~~of ~~operations over~~ the ~~next~~matters 12described, ~~months. To~~there ~~the~~is ~~extent~~substantial ~~that~~doubt weas ~~are required~~ to ~~raise~~the ~~additional~~Company's ~~funds~~ability to ~~acquire~~continue ~~research and~~as ~~growing~~a ~~facilities,~~going ~~and~~concern towithout ~~cover~~a significant ~~costs~~infusion of ~~operations~~capital. At June 30, we2017, ~~intend~~the toCompany dohad soinsufficient ~~through~~operating ~~additional~~revenues ~~public~~and orcash ~~private~~flow ~~offerings~~to ofmeet ~~debt~~its orfinancial ~~equity securities~~obligations. There ~~are~~can be no ~~commitment~~ orassurance ~~arrangements~~that ~~for other offerings~~management will be successful in ~~place,~~implementing noits ~~guaranties~~plans. The ~~that any~~consolidated ~~such~~financial ~~financings~~statements ~~would~~do benot ~~forthcoming,~~include orany asadjustments tothat might result from the ~~terms~~outcome of ~~any~~this ~~such financings~~uncertainty.

~~Any~~We anticipate ~~future~~that ~~financing~~we ~~may~~will ~~involve~~have ~~substantial~~to ~~dilution~~raise additional capital to ~~existing~~ ~~investors~~fund operations over the next 12 months. WeTo ~~had~~the ~~been~~extent ~~relying~~that we onare ~~our~~required ~~common~~to ~~stock~~raise additional funds to ~~pay~~acquire ~~third~~research ~~parties~~and ~~for~~growing ~~services~~facilities, ~~which~~and ~~has~~to ~~resulted~~cover incosts ~~substantial~~of operations, we intend ~~dilution~~to do so through additional public or private offerings of debt or equity securities. There are no commitment or arrangements for other offerings in place, no guaranties that any such financings would be forthcoming, or as to ~~existing~~the ~~investors~~terms of any such financings.

3Any future financing may involve substantial dilution to existing investors. We ~~FAIR~~had ~~VALUE~~been ~~MEASUREMENTS~~relying ~~AND~~on our common stock to pay ~~DISCLOSURES~~third parties for services which has resulted in substantial dilution to existing investors.

~~ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value~~3. ~~That framework provides a fair value hierarchy that prioritizes the inputs to~~ ~~valuation~~FAIR ~~techniques~~VALUE ~~used~~MEASUREMENTS toAND measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).DISCLOSURES

4ASC Topic 820, Fair Value Measurement, establishes a framework for measuring fair value. ~~RELATED~~ ~~PARTY~~That ~~TRANSACTIONS~~framework provides a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements).

~~At March 31, 2017, a total of $104,200 (December 31, 2016:~~4. ~~$14,200)~~ RELATED inPARTY ~~Accrued Management Fees Payable was due to the Company’s CEO/Director, Raymond C. Dabney.~~TRANSACTIONS

At June ~~March 31~~30, 2017, a total ~~Prepaid management fees~~ of $45139,~~000~~ 180 (December 31, 2016: ~~Prepaid~~ $5214,~~500~~200) ~~advanced~~in Accrued Management Fees Payable was due to the Company’s CEO/Director, ~~Mario~~Raymond ~~Lap~~C. Dabney.

At June ~~March 31~~30, 2017, a total Prepaid management fees of ~~$15~~37,~~000~~500 (December 31, 2016: Prepaid $3052,~~000~~500) inadvanced ~~Accrued Management Fees Payable was due~~ to the Company’s ~~COO/~~ Director, ~~Robert~~Mario ~~Kane~~Lap.

At June ~~March 31~~30, 2017, a total of $5260,~~500~~000 (December 31, 2016: Prepaid $5230,~~500~~000) in ~~loans~~Accrued ~~payable~~Management Fees Payable was due to the Company’s ~~CFO~~ COO/Director, Robert Kane~~, through his company, R Kane Holding Inc~~.~~, secured by a non-interest bearing promissory note due within 30 days of Michigan Green Technologies (50.1% controlled by the Company) liquidating shares in Cannabis Science, Inc. to repay the debt.~~

At June ~~March 31~~30, 2017, ~~the~~a ~~Company~~total ~~owes~~of $1152,~~871~~500 (December 31, 2016: $1152,~~871~~500) in loans payable was due to ~~Crown~~the ~~Baus~~Company’s ~~Capital~~CFO, ~~Corp.~~Robert Kane, through ~~which~~his ~~advanced~~company, aR ~~total~~Kane ofHolding ~~$11~~Inc.,~~871~~ ~~for~~secured ~~payment~~by ofa ~~the~~non-interest ~~Company’s~~bearing ~~expenses~~promissory innote ~~July, August~~due ~~and~~within ~~September~~30 days of ~~2015~~Michigan ~~with~~Green Technologies no(50.1% ~~interest~~controlled ~~and~~by nothe ~~security.~~Company) ~~Crown~~liquidating ~~Baus~~shares ~~Capital~~in ~~Corp.~~Cannabis isScience, aInc. ~~company~~to ~~controlled~~repay bythe ~~Raymond C~~debt. ~~Dabney.~~

~~F-7~~At June 30, 2017, the Company owes $11,871 (December 31, 2016: $11,871) to Crown Baus Capital Corp., which advanced a total of $11,871 for payment of the Company’s expenses in July, August and September of 2015 with no interest and no security. Crown Baus Capital Corp. is a company controlled by Raymond C. Dabney.

~~As of March 31, 2017, the Company owes $101,882 (December 31, 2016: $101,882) in loan payable to a stockholder, Interstate 101 that is non~~F-~~interest bearing and due on demand with no security. The loan originated between April 1, 2015 and August 19, 2016 for various expenses of the Company.~~7

AtAs of ~~March~~June 3130, 2017, the Company owes $3101,~~165~~882 (December 31, 2016: $3101,~~165~~882) in loan payable to ~~Castor Management Services,~~ a ~~shareholder of the Company~~stockholder, ~~with~~Interstate no101 that is non-interest ~~and~~bearing ~~no security~~ and is due on demand with no security. The loan originated onbetween ~~August~~April 141, 2015 and August 19, 2016 for various expenses of the Company.

At June ~~March 31~~30, 2017, athe ~~total~~Company ofowes $~~191~~3,~~344~~165 (December 31, 2016: $~~191~~3,~~344~~165) in ~~loans~~loan payable ~~was due~~ to ~~Bogat~~Castor ~~Family~~Management ~~Trust~~Services, a shareholder of ~~which~~the ~~Raymond~~Company, ~~Dabney~~with ~~the~~no ~~Company’s~~interest ~~Director~~and no security and ~~President/CEO~~is due on demand. The loan originated on August 14, 2015 for expenses of asthe ~~trustee~~Company.

At June ~~March 31~~30, 2017, a total of $99191,~~463~~344 (December 31, 2016: $93191,~~885~~344) in loans payable was due to ~~MJR~~Bogat BVFamily Trust, ~~owned~~of bywhich ~~Mario~~Raymond Dabney ~~Lap~~the ~~director~~Company’s ~~and~~Director ~~director~~ and ~~officer~~President/CEO ofas ~~EU subsidiaries~~trustee.

At June ~~March 31~~30, 2017, $~~447~~106,186 (December 31, 2016: $~~447~~93,885) was due to ~~Robert~~MJR ~~Melamede~~BV, ~~former~~owned ~~CEO~~by Mario Lap director and director and officer of EU subsidiaries.

At June ~~March 31~~30, 2017, ~~a total of~~ $~~52,160~~ 447 (December 31, 2016: $~~23,378~~447) ~~in loans payable~~ was due to ~~Drue~~Robert ~~Young~~Melamede, aformer ~~shareholder of the Company, with no interest and no security and is due on demand~~CEO. ~~The loan originated from January 11, 2016 to March 31, 2017 for expenses of the Company.~~

At June ~~March 31~~30, 2017, a total of $2088,~~502~~ 167 (December 31, 2016: $2023,~~502~~378) in loans payable was due to ~~Intrinsic~~Drue ~~Venture Corp.~~Young, a shareholder of the Company, with no interest and no security and is due on demand. The loan originated from ~~April~~January 2211, ~~2011~~2016 to ~~December~~June 3130, ~~2014~~2017 for expenses of the Company.

At June ~~March 31~~30, 2017, ~~the~~a ~~Company~~total ~~held~~of 7$20,~~500,000~~502 ~~common shares in the OmniCanna Health Solutions, Inc.~~ (~~prior~~December ~~to April 24~~31, ~~2014, the name was Endocan Corporation) (OTCBB~~2016: ~~ENDO~~$20,502) ~~(“OmniCanna”) representing~~in ~~approximately~~loans ~~2.89%~~payable ofwas ~~the~~due ~~issued~~to ~~and~~Intrinsic ~~outstanding~~Venture ~~shares of OmniCanna, of which 5,000,000 common shares were acquired at a fair market value of $150,000 or $0~~Corp.~~03 per share on December 12~~, ~~2012 and 2,500,000 common shares were acquired at~~ a ~~fair~~shareholder ~~market value~~ of ~~$262,250~~the ~~or $0.1049 per share on February 8~~Company, ~~2013. The~~with ~~5,000,000~~no ~~common shares were received as consideration for the sale of its rights and~~ interest ~~in the Dupetit Natural Products GmbH joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement~~ and ~~the~~no ~~2,500,000~~security ~~common shares were received as consideration for the sale of its rights~~ and ~~interest in~~is ~~the~~due ~~Maliseet~~on ~~joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement~~demand. The ~~value~~loan oforiginated ~~the~~from ~~shares at~~April ~~March 31~~22, ~~2017~~2011 ~~was determined~~ to ~~be $0.032 per share or $240,000 with the Company recording unrealized gain under the Equity Investee rules for the three months ended March 31, 2017 and the value of the shares at~~ December 31, ~~2016 was determined to be~~ $02014.~~025 per share or $187,500.~~

~~Convertible~~At June ~~Notes~~30, ~~Payable~~2017, the Company held 7,500,000 common shares in the OmniCanna Health Solutions, Inc. (prior to ~~Royalty~~April ~~Management~~24, ~~Services~~2014, the ~~Corp~~name was Endocan Corporation) (OTCBB: ENDO) (“OmniCanna”) representing approximately 2.89% of the issued and outstanding shares of OmniCanna, aof ~~company~~which ~~owned~~5,000,000 bycommon shares were acquired at a ~~family~~fair ~~member~~market value of ~~Mr.~~$150,000 ~~Raymond~~or C$0.03 ~~Dabney,~~per ~~CEO/Director~~share ofon ~~the~~December 12, ~~Company~~2012 and 2,500,000 ~~entered~~common ~~into~~shares were acquired at a ~~management~~fair ~~agreement with~~market ~~the~~value ~~Company~~of $262,250 or $0.1049 per share on ~~September~~February 158, ~~2015~~2013. The 5,000,000 common shares were received as consideration for ~~accounting~~the ~~services,~~sale ~~websites~~of ~~development~~its rights and ~~maintenance,~~interest ~~office~~in ~~management,~~the ~~management~~Dupetit Natural ~~and~~Products ~~payments~~GmbH ~~for~~joint-venture ~~travel,~~operating ~~promotion~~agreement to OmniCanna under an Asset Purchase Agreement and ~~entertainments~~the 2,500,000 ~~shareholders~~common ~~communications~~shares were received as consideration for the sale of its rights and ~~payment~~interest ~~services~~in ~~totaled~~the ~~$860~~Maliseet joint-venture operating agreement to OmniCanna under an Asset Purchase Agreement. The value of the shares at June 30,~~790~~ ~~and~~2017 was determined to be $~~860~~0.0181 per share or $135,~~790~~750 atwith ~~March~~the 31Company recording unrealized loss under the Equity Investee rules for the six months ended June 30, 2017 and the value of the shares at December 31, 2016 ~~respectively~~was determined to be $0.025 ~~See~~per ~~Note~~share 5or $187,500.

OnConvertible Notes ~~November~~Payable 5,to ~~2014,~~Royalty ~~the~~Management ~~Company~~Services ~~transitioned to~~Corp., ~~equity~~a ~~method~~company ~~investee~~owned ~~account~~by ~~for~~a ~~the~~family ~~OmniCanna~~member ~~shares~~of ~~pursuant~~Mr. toRaymond ~~ASC~~C. ~~323 recording $247~~Dabney,~~500~~ ~~as the fair value~~ CEO/Director of the ~~shares to~~Company, ~~its~~entered ~~equity~~into ~~method~~a ~~investee~~management ~~account. On~~agreement ~~December~~with ~~31, 2016,~~ the Company ~~recorded~~on anSeptember ~~impairment~~15, on2015 ~~the~~for ~~equity~~accounting ~~method~~services, ~~investee~~websites ~~account~~development ofand ~~$114~~maintenance,~~000~~ inoffice ~~relation to the shares. Robert Kane~~management, ~~CFO~~management and ~~director~~payments offor ~~the~~travel, ~~Company~~promotion isand ~~also~~entertainments, shareholders ~~the~~communications ~~CFO~~ and apayment ~~director of~~services ~~OmniCanna.~~totaled ~~Chad S. Johnson~~$1, ~~Esq.~~235,790 ~~COO, general counsel~~ and a$860,790 ~~director~~at isJune ~~also~~30, a2017 ~~director~~ and ~~general~~December ~~counsel for Omnicanna. Raymond Dabney~~31, ~~CEO has 10~~2016 respectively.~~78%~~ ~~equity~~See ~~interest~~Note ~~in Omniccanna Health Solutions, Inc~~5. ~~as of March 31, 2017.~~

~~F-8~~On November 5, 2014, the Company transitioned to equity method investee account for the OmniCanna shares pursuant to ASC 323 recording $247,500 as the fair value of the shares to its equity method investee account. On December 31, 2016, the Company recorded an impairment on the equity method investee account of $114,000 in relation to the shares. Robert Kane, CFO and director of the Company is also the CFO and a director of OmniCanna. Chad S. Johnson, Esq., COO, general counsel and a director is also a director and general counsel for Omnicanna. Raymond Dabney, CEO has 10.78% equity interest in Omniccanna Health Solutions, Inc. as of June 30, 2017.

~~For the Three months ended March 31, 2017, the following related party stock~~F-~~based compensation was recorded:~~8

Related Party	Position		Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
		$	415,000

For the Six months ended June 30, 2017, the following related party stock-based compensation was recorded:

1 Including compensation to entities beneficially owned/control by the related parties


Related Party	Position	Amount
Alfredo Bernardi Dupetit	President & CEO of Cannabis Science Europe GmbH	$	415,000
Dr. Allen Herman	Chief Medical Officer		595,000
		$	1,010,000

~~See~~1 Including ~~Note~~compensation ~~6 -Equity Transactions for details of stock issuances~~ to ~~director~~entities ~~and~~beneficially ~~officers~~owned/control ~~for~~by ~~services~~the ~~rendered.~~related parties

~~Mario Lap, a director of the Company and director and officer~~See ofNote ~~its~~6 ~~European~~-Equity ~~subsidiaries,~~Transactions isfor ~~conducting~~details ~~various business activities~~ of ~~the~~stock ~~Company~~issuances ~~in Spain under his personal name and/or his personal holding companies MJR BV, MLS Lap BV and Cannabis Agency BV until such time as the Company is able~~ to ~~establish~~director ~~a Spanish subsidiary to conduct its own business operations~~ and ~~activities,~~officers ~~including but not limited to: operating lease~~ for ~~farms, asset~~services ~~purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time~~rendered. ~~The Company anticipates having the Spanish subsidiary setup soon at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.~~

~~Alfredo Dupetit-Bernardi~~Mario Lap, ~~International~~a ~~Product~~director ~~Development~~ of the Company and ~~President~~director &and ~~CEO~~officer of ~~Cannabis~~its ~~Science~~European ~~Europe GmbH~~subsidiaries, is conducting ~~product~~various ~~development~~business ~~through~~activities of the ~~purchase~~Company ofin ~~cannabis~~Spain ~~products from~~under his personal ~~company~~name and/or his personal holding companies MJR BV, ~~Dupetit~~MLS ~~Natural~~Lap ~~Products~~BV ~~GmbH~~and Cannabis Agency BV until such time as the Company is able to establish a Spanish subsidiary to conduct its own business operations and activities, including but not limited to: operating lease for farms, asset purchases, office and equipment, personnel employment and other business and operating activities as may be required from time-to-time. The Company anticipates having the Spanish subsidiary setup soon at which time Mario Lap under fiduciary duty will transfer all business operating activities, agreements, and assets to the Company.

~~On August 10, 2016, a total of $975,407 in Management Fees~~Alfredo ~~Payable accumulated from February 2012 to June 30, 2016 was converted into a two~~Dupetit-~~year Convertible Promissory Note to Raymond C. Dabney~~Bernardi, ~~CEO/Director~~International ofProduct ~~the~~Development Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 in accordance with ASC 470-20-30-8 and ~~amortize~~President it& ~~over~~CEO ~~the life~~ of ~~the~~Cannabis ~~Note.~~Science ~~The~~Europe ~~Company has partially reduced $250~~GmbH,~~000~~ asis ~~result~~conducting ~~of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted~~product ~~common~~development ~~stock~~through ~~at $0.001 a share. In addition,~~ the ~~Company~~purchase ~~paid $55,000 in expenses for Mr. Dabney in 2016. The balance~~ of ~~the~~cannabis ~~Convertible Promissory~~products ~~Note~~from ashis ofpersonal ~~March 31~~company, ~~2017~~Dupetit ~~was~~Natural ~~$670,407~~Products ~~(December 31, 2016: $670,407)~~GmbH.

~~Notes~~On August ~~payable~~10, to2016, ~~Embella~~a ~~Holdings~~total ~~Ltd.~~of ~~totaled~~ $1975,~~108~~407 in Management Fees Payable accumulated from February 2012 to June 30,~~896~~ 2016 was converted ~~and~~into $1a two-year Convertible Promissory Note to Raymond C. Dabney,~~108~~ CEO/Director of the Company. At the election of the note holder,~~896~~ it can be converted into common stocks of the Company at ~~March~~the 31par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975,407 ~~2017~~in accordance with ASC 470-20-30-8 and amortize ~~December~~it 31over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 ~~respectively~~Rule 144 restricted common stock at $0. As001 ofa ~~March~~share. ~~31,~~In ~~2017~~addition, the Company ispaid $55,000 in ~~default~~expenses ~~on the~~for ~~promissory~~Mr. ~~notes~~Dabney ~~due~~in ~~and~~2016. isThe ~~negotiating~~balance ~~with~~of the ~~debtor~~Convertible toPromissory ~~extend~~Note ~~the~~as ~~date.~~of ~~See~~June ~~Note~~30, 52017 was $670,407 (December 31, 2016: $670,407).

Notes payable to ~~Intrinsic~~Embella ~~Capital~~Holdings ~~Corp~~Ltd. totaled $~~231~~1,~~260~~ 108,896 and $~~231~~1,~~260~~108,896 at ~~March~~June 3130, 2017 and December 31, 2016, respectively. As of June 30, 2017, the Company is in default on the promissory notes due and is negotiating with the debtor to extend the date. See Note 5.

~~Between~~Notes payable ~~January 1, 2015~~ to ~~March~~Intrinsic 7,Capital ~~2015, R~~Corp. ~~Kane~~totaled ~~Holding Inc.~~$231,260 ~~a company owned by Mr. Robert Kane, director~~ and ~~CFO~~$231,260 ~~had~~at ~~advanced~~June ~~$52~~30,~~500~~ ~~into~~2017 ~~Michigan~~and ~~Green~~December ~~Technologies~~31, ~~LLC~~2016, ~~which is 50~~respectively.1% ~~controlled~~See ~~by the Company as Loan Payable to R~~Note 5. ~~Kane Holding Inc.~~

OnBetween January ~~July 25~~1, ~~2014,~~2015 ~~Bogat~~to ~~Family~~March ~~Trust~~7, ~~with Raymond Dabney as trustee~~2015, ~~representing~~R. aKane ~~majority~~Holding ~~of Series A preferred stockholders~~Inc., ~~signed~~ a ~~resolution~~company toowned ~~approve~~by anMr. ~~amendment~~Robert toKane, ~~the~~director ~~certificate of designation preferences~~ and ~~rights~~CFO, ~~for~~had ~~Series~~advanced A$52,500 into ~~preferred~~Michigan ~~shares.~~Green ~~Pursuant to the amendment filed with the Nevada Secretary of State~~Technologies, ~~the voting rights of Series A preferred stockholders was changed from 1~~LLC,~~000~~ ~~votes~~which ~~per~~is ~~share to 67~~50.1% ofcontrolled by the ~~total~~Company ~~vote on~~as ~~all~~Loan ~~shareholder~~Payable ~~matters~~to R. No ~~common~~Kane ~~stockholders~~Holding ~~voted on this amendment~~Inc.

~~F-9~~On July 25, 2014, Bogat Family Trust, with Raymond Dabney as trustee, representing a majority of Series A preferred stockholders, signed a resolution to approve an amendment to the certificate of designation preferences and rights for Series A preferred shares. Pursuant to the amendment filed with the Nevada Secretary of State, the voting rights of Series A preferred stockholders was changed from 1,000 votes per share to 67% of the total vote on all shareholder matters. No common stockholders voted on this amendment.

~~5. NOTES PAYABLE~~F-9

As of March 31, 2017, a total of $1,590,715 (December 31, 2016: $1,506,745) of notes payable are due mostly to stockholders that are non-interest bearing and are due 12 months from the date of issue and loan origination beginning on January 31, 2012 through December 31, 20165. ~~$1,340,156 of the Promissory notes~~ ~~were~~ NOTES in default on March 31, 2017. As of March 31, 2017, a total of $1,531,197 convertible promissory notes (December 31, 2016: $1,531,197) are convertible to common stock of the Company. All promissory notes are unsecured.PAYABLE

~~Notes~~As of ~~payable~~June to30, ~~Embella~~2017, ~~Holdings~~a ~~Ltd~~total ~~that~~of ~~are non-interest bearing totaled~~ $1,~~108~~674,~~896~~685 ~~and~~(December 31, 2016: $1,~~108~~506,~~896~~745) atof ~~March~~notes ~~31,~~payable ~~2017~~are ~~and~~due ~~December~~mostly ~~31,~~to ~~2016,~~stockholders ~~respectively. As~~that ofare non-interest ~~March~~bearing ~~31,~~and ~~2017,~~are ~~the Company~~due is12 inmonths ~~default~~from on the ~~promissory~~date ~~notes~~of ~~due~~issue and isloan ~~negotiating~~origination ~~with~~beginning ~~the~~on ~~debtor~~January to31, ~~extend~~2012 ~~the~~through ~~date~~December 31, 2016.

~~Notes payable to Intrinsic Capital Corp. that are non-interest bearing totaled~~ $~~231~~1,~~260~~340,156 of ~~and~~the ~~$231,260~~Promissory atnotes ~~March~~were ~~31,~~in ~~2017~~default ~~and~~on ~~December~~June 3130, ~~2016, respectively~~2017. As of ~~March~~June 3130, 2017, ~~the~~a ~~Company is~~total inof ~~default~~$1,906,197 onconvertible ~~the~~ promissory notes (December ~~due~~31, ~~and~~2016: is$1,531,197) ~~negotiating~~are ~~with~~convertible ~~the~~to ~~debtor~~common tostock ~~extend~~of the ~~date~~Company. All promissory notes are unsecured.

~~On August 10, 2016, a total of $975,407~~Notes inpayable ~~Management Fees Payable accumulated from February 2012~~ to ~~June~~Embella ~~30,~~Holdings ~~2016~~Ltd ~~was~~that ~~converted~~are ~~into a two~~non-~~year~~interest ~~Convertible~~bearing ~~Promissory Note~~totaled ~~to Raymond C. Dabney~~$1, ~~CEO/Director of the Company. At the election of the note holder~~108,896 itand ~~can be converted into common stocks of the Company at the par value of~~ $~~0.001 a share. The Company has fully recognized the conversion discounts of the Note as prepaid interest to the maximum amount of $975~~1,~~407~~108,896 inat ~~accordance~~June ~~with ASC 470-20-~~30-8, 2017 and ~~will amortize it over the life of the Note. The~~December ~~Company has partially reduced $250~~31,~~000~~ ~~as result of a Debt Settlement Agreement dated August 10,~~ 2016 ~~by issuance of 250~~,~~000,000 Rule~~ ~~144 restricted common stock at $0~~respectively.~~001~~ As aof ~~share.~~June In30, ~~addition~~2017, the Company ~~paid~~is ~~$55,000~~ in ~~expenses~~default ~~for~~on ~~Mr. Dabney in 2016. The balance of~~ the ~~Convertible~~promissory ~~Promissory~~notes ~~Note~~due asand ofis ~~March~~negotiating ~~31, 2017 was $670,407 (December 31, 2016: $670,407). In the three months~~with ~~ended March 31, 2017,~~ the ~~Company~~debtor ~~recorded~~to ~~$83,970~~extend ~~as interest for~~ the ~~amortization, conversion and payment~~date.

OnNotes payable ~~October~~to 1,Intrinsic ~~2016,~~Capital aCorp. ~~total~~that ofare ~~$710,790~~non-interest inbearing ~~Accounts~~totaled ~~Payable for~~$231,260 ~~management~~and ~~fees~~$231,260 ~~accumulated~~at ~~from~~June ~~January~~30, ~~2016~~2017 toand ~~October~~December 131, 2016, ~~was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp~~respectively. AtAs ~~the election~~ of ~~the~~June ~~note~~30, ~~holder~~2017, ~~it can be converted into common stocks of~~ the Company at ~~the~~is ~~par~~in ~~value~~default ofon ~~$0.001~~the apromissory ~~share~~notes ordue ~~other~~and ~~mutually~~is ~~agreed~~negotiating ~~upon~~with ~~price.~~the ~~The~~debtor to ~~Company~~extend ~~has~~the ~~not~~date.

~~recognized~~On August 10, 2016, a total of $975,407 in Management Fees Payable accumulated from February 2012 to June 30, 2016 was converted into a two-year Convertible Promissory Note to Raymond C. Dabney, CEO/Director of the Company. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share. The Company has fully recognized the conversion discounts of the Note ~~due~~as prepaid interest to the ~~uncertainty~~ ofmaximum ~~the~~amount ~~price~~of $975,407 in accordance with ASC 470-20-2530-8 and will amortize it over the life of the Note. The Company has partially reduced $250,000 as result of a Debt Settlement Agreement dated August 10, 2016 by issuance of 250,000,000 Rule 144 restricted common stock at $0.001 a share. In addition, the Company paid $55,000 in expenses for Mr. Dabney in 2016. The balance of the Convertible Promissory Note as of ~~March~~June 3130, 2017 was $~~710~~670,~~790~~ 407 (December 31, 2016: $~~710~~670,~~790~~407). In the six months ended June 30, 2017, the Company recorded $167,940 as interest for the amortization, conversion and payment.

On October ~~December 31~~1, 2016, a total of $~~150~~710,~~000~~790 in Accounts Payable for management fees accumulated from ~~November~~January 1, 2016 to ~~December~~October 311, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp. At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The ~~company~~Company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of ~~March 31~~June 30, 2017 was $~~150~~710,~~000~~790 (December 31, 2016: $~~150~~710,~~000~~790). In the six months ended June 30, 2017 the Company recorded $355,395 as interest for the amortization, conversion and payment.

6On December 31, 2016, $150,000 in Accounts Payable for management fees accumulated from November 1, 2016 to December 31, 2016 was converted into a one-year Convertible Promissory Note to Royalty Management Services Corp. ~~EQUITY~~ ~~TRANSACTIONS~~At the election of the note holder, it can be converted into common stocks of the Company at the par value of $0.001 a share or other mutually agreed upon price. The company has not recognized the conversion discounts of the Note due to the uncertainty of the price in accordance with ASC 470-20-25. The balance of the Convertible Promissory Note as of June 30, 2017 was $150,000 (December 31, 2016: $150,000). In the six months ended June 30, 2017 the Company recorded $75,000 as interest for the amortization, conversion and payment.

~~The~~On May ~~Company~~31, is2017, ~~authorized~~$375,000 in Accounts Payable for management fees accumulated from January 1, 2017 to ~~issue~~May 331,~~000,000,000~~ ~~shares~~2017 ofwas converted ~~common~~into ~~stock~~a ~~with~~one-year aConvertible ~~par~~Promissory ~~value~~Note ofto ~~$0.001~~Royalty ~~per~~Management ~~share~~Services Corp. ~~These~~ ~~shares~~At ~~have~~the ~~full~~election ~~voting~~of ~~rights. There~~the ~~were~~note 2holder,~~443,355,296~~ ~~and 2,350,355,296~~it ~~issued~~can ~~and~~be converted ~~outstanding~~into ascommon stocks of ~~March~~the ~~31,~~Company ~~2017~~at ~~and~~the ~~December~~par ~~31,~~value ~~2016,~~of ~~respectively~~$0.001 ~~The~~a ~~current~~share ~~authorized~~or ~~common~~other ~~stock of~~mutually ~~3,000,000,000~~agreed ~~shares~~upon ~~will~~price. The company has not berecognized ~~sufficient~~the ifconversion ~~and~~discounts ~~when~~of the ~~debt~~Note ~~holders~~due ofto ~~convertible~~the ~~promissory~~uncertainty ~~notes~~of ~~elect~~the toprice ~~convert~~in ~~the debts~~accordance ~~into~~with ~~common~~ASC ~~shares~~470-20-25. The ~~Company~~balance ~~intends~~of tothe ~~file~~Convertible ~~for~~Promissory anNote ~~increase~~as inof ~~the~~June ~~number~~30, ~~shares~~2017 inwas ~~authorized~~$375,000 ~~common~~(December ~~stock~~31, ~~once~~2016: $0). In the six months ended ~~required~~June ~~updated~~30, ~~financial~~2017 ~~reportings~~the ~~have~~Company ~~been~~recorded ~~filed~~$31,250 ~~with~~as interest for the ~~Securities~~amortization, ~~Exchange~~conversion ~~Commission~~and payment.

~~The Company is also authorized to issue 100,000,000 shares of common stock, Class A with a par value of $0.001 per share. These shares have~~ F-10 ~~votes per share. There were 0 issued and outstanding as of March 31, 2017 and December 31, 2016.~~

~~F-10~~6. EQUITY TRANSACTIONS

The Company is ~~also~~ authorized to issue 13,000,000,000 shares of ~~preferred~~common stock with a par value of $0.001 per share. These shares have full voting rights. There ofwere ~~67%~~2,461,855,296 onand ~~all~~2,350,355,296 ~~shareholder~~issued ~~matters~~and ~~pursuant~~outstanding toas ~~amended certificate~~ of ~~designation~~June ~~filed~~30, ~~with~~2017 ~~the~~and ~~Nevada~~December ~~Secretary~~31, 2016, ~~of State~~respectively. ~~There~~ ~~were~~The 1current authorized common stock of 3,000,000,000 ~~issued~~shares will not be sufficient if and ~~outstanding~~when asthe debt holders of ~~March~~convertible ~~31,~~promissory ~~2017~~notes elect to convert the debts into common shares. The Company intends to file for an increase in ~~and~~the ~~December~~number ~~31,~~shares ~~2016~~in authorized common stock once the required updated financial reportings have been filed with the Securities Exchange Commission.

AsThe Company ~~set~~is ~~out~~also ~~below~~authorized to issue 100,000,000 weshares ~~have~~of ~~issued~~common ~~securities~~stock, inClass ~~exchange~~A ~~for~~with a par value of $0.001 per share. These ~~services,~~shares ~~properties~~have ~~and~~10 ~~for~~votes ~~debt,~~per ~~using~~share. There ~~exemptions~~were ~~available~~0 ~~under~~issued ~~the~~and ~~Securities~~outstanding ~~Act~~as of ~~1933~~June 30, 2017 and December 31, 2016.

~~During~~The Company ~~the~~is ~~three~~also ~~months~~authorized ~~ended~~to ~~March~~issue 311, ~~2017~~000,000 ~~the~~shares ~~Company~~of preferred stock. These shares have full voting rights of 67% on ~~issued~~all 58shareholder matters pursuant to amended certificate of designation filed with the Nevada Secretary of State. There were 1,000,000 ~~common~~issued ~~stock~~and ~~for~~outstanding ~~services~~as ~~under~~of ~~various~~June ~~executive~~30, 2017 and ~~consulting~~December ~~agreements~~31, ~~as follows:~~2016.

OnAs set ~~February~~out 16below, ~~2017,~~we ~~the~~have ~~Company~~ issued ~~5,000,000~~ ~~shares~~securities ofin ~~R144~~exchange ~~restricted~~for ~~common~~services, ~~stock~~properties toand afor ~~consultant with a fair market value of $350~~debt,~~000~~ ~~for~~using ~~legal~~exemptions ~~and~~available ~~general~~under ~~consulting~~the ~~services~~Securities ~~under~~Act aof ~~consulting agreement dated January 13, 2017~~1933.

OnDuring the ~~February~~six 16months ended June 30, 2017, the Company issued 10 66,~~000~~500,000 ~~shares S-8 registered free-trading~~ common stock tofor aservices ~~consultant~~under ~~with~~various aexecutive ~~fair market value of $700,000 for legal~~ and ~~general~~ consulting agreements ~~services~~as ~~pursuant to a consulting agreement dated January 13, 2017.~~follows:

On February ~~March 2~~16, 2017, the Company issued 35,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $~~271~~350,~~500~~000 for legal and general consulting services ~~pursuant~~under to a ~~two-year~~ consulting agreement dated January 13, 2017.

On February ~~March 7~~16, 2017, the Company issued 1510,000,000 shares S-8 registered free -trading common stock ~~under~~to ~~the~~a ~~2016~~consultant ~~Equity Award Plan B~~ with a fair market value of $1700,~~270,500~~000 for legal and general consulting services ~~under~~ pursuant to a consulting agreement dated ~~March~~January 713, 2017.

On March 132, 2017, the Company issued 103,000,000 shares ~~S-8 registered~~of ~~free~~R144 ~~trading~~restricted common stock ~~under~~to ~~the~~a ~~2016~~consultant ~~Equity Award Plan B~~ with a fair market value of $~~883~~271,~~000~~500 for consulting services pursuant to a two-year consulting agreement ~~dated July 6 2016~~.

On March 137, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,~~324~~270,500 for consulting services ~~pursuant~~ tounder a consulting agreement dated ~~April~~March 297, ~~2015~~2017.

On ~~Stock~~March ~~Options:~~13, 2017, the Company issued 10,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $883,000 for consulting services pursuant to a consulting agreement dated July 6 2016.

~~The~~On March ~~following~~13, ~~options~~2017, ~~were~~the Company issued to15,000,000 shares S-8 registered free trading common stock under the ~~Company’s~~2016 Equity Award Plan ~~V.P~~B ofwith ~~investor~~a ~~relations,~~fair ~~CFO~~market ~~and~~value ~~Director~~of $1,324,500 for consulting services ~~under~~pursuant to a ~~September~~consulting ~~16,~~agreement ~~2011~~dated ~~agreement:~~April 29, 2015.

~~(i)~~On May ~~the~~5, ~~option~~2017, tothe ~~purchase~~Company ~~100~~issued 7,000,000 shares of R144 restricted common ~~shares~~stock atto ~~ten~~a ~~cents~~consultant (with a fair market value of $~~0.10)~~469,000 for ~~per~~consulting ~~share;~~services pursuant to a one year consulting agreement.

~~(ii)~~On May ~~the~~17, ~~option~~2017, tothe ~~purchase~~Company issued 1,500,000 shares of R144 restricted common ~~shares~~stock atto ~~thirty-five~~a ~~cents~~consultant (with a fair market value of $~~0.35)~~93,000 ~~per~~for ~~share;~~consulting ~~and~~services pursuant to a three-month Marketing agreement.

~~(iii) the option to purchase 100,000 common shares at twenty cents ($0.20) per share;~~F-11

~~(iv) the option to purchase 1,000,000 common shares at fifty cents ($0.50) per share.~~Stock Options:

OnThe following ~~January~~options ~~13,~~were ~~2017,~~issued to the Company’s ~~issued 10,000,000~~V.P ~~shares S-8 registered free-trading common stock under an Option Agreement~~ of ~~2016~~investor ~~Equity~~relations, ~~Award~~CFO ~~Plan~~and BDirector ~~with~~for ~~exercise price~~services atunder ~~$0.05 and~~ a ~~fair market value of $700~~September 16,~~000~~ to2011 ~~a consultant pursuant to a consulting~~ agreement.:

On(i) ~~January~~the ~~24,~~option ~~2017,~~to ~~the~~purchase ~~Company issued 10~~100,000~~,000~~ ~~shares S-8 registered free-trading~~ common ~~stock~~shares ~~under~~at anten ~~Option~~cents ~~Agreement of 2016 Equity Award Plan B with exercise price at~~ ($0.0410) ~~and~~per ~~a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH.~~share;

On(ii) ~~March 27, 2017,~~ the ~~Company~~option ~~issued~~to 15purchase 500,000~~,000~~ common shares ~~S-8 registered~~at ~~free~~thirty-~~trading~~five ~~common~~cents ~~stock under the 2016 Equity Award Plan B with exercise price at~~ ($0.~~075~~35) ~~and~~per ashare; ~~fair market value of $1,140,000 to a consultant pursuant to a five-year consulting agreement.~~and

~~F-11~~(iii) the option to purchase 100,000 common shares at twenty cents ($0.20) per share;

A(iv) ~~summary of~~ the ~~status of the Company’s~~ option ~~grants as~~to ofpurchase ~~March 31~~1,000,000 ~~2017~~common ~~and~~shares ~~the~~at ~~changes~~fifty ~~during~~cents ~~the~~($0.50) ~~period~~per ~~then ended is presented below:~~share.

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.0690
Granted		35,000,000	$	0.0606
Exercised		35,000,000	$	0.0606
Outstanding March 31, 2017		11,700,000	$	0.0680
Options exercisable at March 31, 2017		11,700,000	$	0.0680

On January 13, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.05 and a fair market value of $700,000 to a consultant pursuant to a consulting agreement.

~~1,700,000 shares of these options at an exercise price of~~On ~~$0.415~~January a24, ~~share~~2017, dothe ~~not~~Company ~~expire~~issued ~~and~~10,000,000 ~~continuing~~shares ~~indefinitely~~S-8 ~~for~~registered ~~the~~free-trading ~~duration~~common ofstock ~~existing~~under ~~management~~an ~~agreement~~Option ~~and~~Agreement ~~services~~of ~~thereunder~~2016 ~~with~~Equity ~~Robert~~Award ~~Kane.~~Plan ~~The~~B ~~weighted~~with ~~average~~exercise ~~fair~~price ~~value~~ at ~~date~~$0.04 ofand ~~grant~~a ~~for~~fair ~~options~~market ~~during~~value ~~year~~of ~~ended March 31~~$815,000 ~~2017~~to ~~was~~Alfredo ~~estimated~~Dupetit-Bernardi, ~~using~~President/CEO ~~the~~of ~~Black-Scholes~~Cannabis ~~option~~Science ~~valuation~~Europe ~~model with the following:~~GmbH.

Average expected life in years for outstanding options	1.56	Years
Average risk-free interest rate	2.50	%
Average volatility	130.98	%
Dividend yield	0	%

On March 27, 2017, the Company issued 15,000,000 shares S-8 registered free-trading common stock under the 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant pursuant to a five-year consulting agreement.

7On April 18, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0. ~~EQUIPMENT~~02 ~~AND~~and ~~GREENHOUSE~~a fair market value of $829,000 to Chief Medical Officer, Dr. Allen Herman.

			Accumulated		March 31, 2017		Dec. 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482		5,779		703		0
Software		5,000		5,000		0		0
		14,482		13,779		703		0
Greenhouse	$	330,026		—	$	330,026	$	0
Total	$	344,508	$	13,779	$	330,729	$	0

A summary of the status of the Company’s option grants as of June 30, 2017 and the changes during the period then ended is presented below:

8. PROPERTY FARMING RIGHTS

	Shares		Weighted-Average Exercise Price
Outstanding December 31, 2016		11,700,000	$	0.0690
Granted		45,000,000	$	0.0494
Exercised		45,000,000	$	0.0494
Outstanding June 30, 2017		11,700,000	$	0.0688

Options exercisable at June 30, 2017		11,700,000	$	0.0688

~~On March 24~~1, ~~2016~~700, ~~the Company entered a 15 years Joint Venture~~000 ~~Agreement~~shares ~~with~~of ~~the Ft.~~these ~~McDermitt~~options ~~Allotment~~at ~~land~~an ~~Allotees,~~average ~~which~~exercise isprice onof ~~the Ft~~$0.415 ~~McDermitt~~a ~~Tribal Reservation~~share, ~~Raymond~~do C.not ~~Dabney University,~~expire ~~American Education Consulting Group~~ and ~~Cannabis~~continuing ~~Science,~~indefinitely ~~Inc.~~ for ~~a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both~~ the ~~Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two~~duration ~~initial payments~~ of ~~$50,000~~existing ~~for farming~~management ~~rights~~agreement and ~~initial~~services ~~development~~thereunder ofwith ~~two~~Robert ~~one~~Kane. ~~(1)~~The ~~acre~~weighted ~~parcels~~average offair ~~land~~value ~~located~~at indate ~~Fort McDermitt Tribal Reservation in the State~~ of ~~Nevada,~~grant ~~USA. Each one (1) acre parcel of land is specifically designated~~ for ~~placement~~options noduring ~~more~~year ~~than~~ended ~~twelve~~June ~~(12) three (3~~30,~~000)~~ ~~square~~2017 ~~foot~~was ~~greenhouses~~estimated ~~for~~using the ~~production~~Black-Scholes ofoption ~~Cannabis~~valuation ~~and~~model ~~all~~with ~~Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of~~ the ~~Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.~~following:

F-12


Average expected life in years for outstanding options	1.38	Years
Average risk-free interest rate	2.50	%
Average volatility	136.071	%
Dividend yield	0	%

On October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twentyF-~~five (25) years.~~12

On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C7. ~~Dabney University to provide general support with~~ ~~developing,~~ EQUIPMENT ~~cultivating~~AND ~~and~~GREENHOUSE processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

On December 18, 2016, the Company enter six (6) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

			Accumulated		June 30, 2017		December 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Computer	$	6,482		5,875		607		0
Software		5,000		5,000		0		0
		11,482		10,875		607		0
Greenhouse	$	330,026		3,667	$	326,359	$	0
Total	$	341,508	$	14,542	$	326,966	$	0

On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C8. ~~Dabney University~~ toPROPERTY ~~provide~~FARMING general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.RIGHTS

			Accumulated		March 31, 2017		Dec. 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	3,056	$	46,944	$	47,778
Washoe Tribal Allotment Lands		640,000		7,452		632,548		638,948
		690,000	$	10,508		679,492		686,726
Operating capital for Washoe Lands	$	60,000			$	60,000	$	—
Operating capital for Winnemucca Lands		65,000		—		65,000		65,000
	$	125,000	$	—		125,000		65,000
Total	$	815,000	$	10,508	$	804,492	$	751,726

On March 24, 2016, the Company entered a 15 years Joint Venture Agreement with the Ft. McDermitt Allotment land Allotees, which is on the Ft. McDermitt Tribal Reservation, Raymond C. Dabney University, American Education Consulting Group and Cannabis Science, Inc. for a total of ten (10), one (1) acre parcels of land. The project is designed to benefit both the Ft. McDermitt Tribe and Members, and Allotment Allottees. Cannabis Science made two initial payments of $50,000 for farming rights and initial development of two one (1) acre parcels of land located in Fort McDermitt Tribal Reservation in the State of Nevada, USA. Each one (1) acre parcel of land is specifically designated for placement no more than twelve (12) three (3,000) square foot greenhouses for the production of Cannabis and all Cannabis related products. All harvested products are to be delivered and sold to qualified licensed distribution centers. The Company is to share 40% of the Adjusted Gross Income after deduction of related operating expenses and cost to build the green houses.

FOn October 24, 2016, the Company entered an Exclusive Master Facilitator Agreement with Members of Winnemucca Tribal Allotment, Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County, Nevada. The Company’s share is 40% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on these lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is five (5) years and up to twenty-13five (25) years.

~~All~~On November ~~equipment~~12, is2016, ~~stated~~the atCompany ~~cost. Maintenance~~entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and ~~repairs~~Raymond ~~are~~C. ~~charged~~Dabney University to ~~expense~~provide asgeneral ~~incurred~~support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the ~~cost~~allotment cc183, a portion of ~~renewals~~the ~~and~~SE ~~betterments~~¼ ~~are~~of ~~capitalized~~section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. ~~Depreciation~~ The Company’s share is ~~computed~~ ~~using~~20% ~~the~~on ~~straight~~all initial non-~~line~~refundable deposits ~~method~~from ~~over~~external investor, and 10% of net profit derived from the ~~estimated~~sale ~~lives~~and distribution of Cannabis/Hemp products grown and manufactured on the ~~related~~land. ~~assets~~Under the agreement, 2the ~~years~~Company ~~for~~will ~~computer,~~be 2provided ~~years~~one (1) acre of land for ~~software,~~research and development 5with ~~years~~placement of no more than 36,000 square feet of greenhouses used for ~~equipment~~cultivation and ~~laboratory~~research ~~equipment~~of ~~and~~Cannabis/Hemp. 3The term of this Exclusive Master Agreement is twenty-five (25) years ~~for~~renewable ~~automobile~~every five (5) years.

~~All~~On December ~~property~~18, ~~farm~~2016, ~~rights~~the ~~are~~Company ~~amortized~~enter six (6) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp ~~over~~with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on 13 one (1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of ~~each~~this ~~respective~~Exclusive ~~agreements~~Master Agreement is twenty-five (25) years renewable every five (5) years.

~~9. EQUITY METHOD INVESTEE~~F-13

On December ~~November 5~~21, ~~2014~~2016, the Company ~~accounted~~enter two (2) Exclusive Master Facilitator Agreement for ~~its~~cultivation ~~investment~~of Medical Marijuana/Hemp ~~and~~with ~~loans~~the Members of Washoe Tribal Allotments in ~~OmniCanna~~Douglas ~~Health~~County, ~~Solutions~~Nevada, ~~Inc.~~together ~~(formerly~~with ~~Endocan~~Free ~~Corporation)~~Spirit ~~using~~Organics, ~~the~~LLC, ~~equity~~American ~~method~~Education Consulting ~~pursuant~~Group and Raymond C. Dabney University to ~~ASC~~provide ~~323~~general –support with developing, cultivating and processing Cannabis/Hemp ~~Investments~~with –Free ~~Equity~~Spirit ~~Method~~Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and ~~Joint~~21, ~~Ventures. In~~located ~~accordance~~in ~~with~~the ~~ASC~~allotment ~~323~~cc183, ~~when~~a portion of the ~~Company~~SE ~~does~~¼ ~~not~~of ~~have~~section a15, ~~controlling~~township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The ~~financial~~Family ~~interest~~Allotment inwill anreceive ~~entity~~$40,000 ~~but~~per ~~exerts~~acre ~~significant~~Good ~~influence~~Faith ~~over~~Non-Refundable ~~the~~Deposit ~~entity~~per development site. The Company’s ~~operating~~share is ~~and~~20% ~~financial~~on ~~policies,~~all ~~the Company~~initial ~~accounts~~non-refundable ~~for~~deposits ~~its~~from ~~investment~~external ininvestor, ~~accordance~~and ~~with~~10% of net profit derived from the ~~equity~~sale ~~method~~and distribution of ~~accounting.~~Cannabis/Hemp ~~This~~products ~~generally~~grown ~~applies~~and tomanufactured ~~cases~~on inthe ~~which~~ land. Under the agreement, the Company ~~owns~~will abe ~~voting~~provided orone ~~economic~~(1) ~~interest~~acre of land ~~between~~for 20research and 50development ~~percent~~with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years.

~~The~~On May ~~accounting~~18, ~~using~~2017, the ~~equity~~Company ~~method~~entered isan inExclusive ~~conjunction with~~Master ~~appointment~~Facilitator ofAgreement ~~Raymond~~with ~~Dabney~~Winnemucca asTribal ~~CEO~~MBS ~~and director~~ of ~~the~~Nevada, ~~Company~~Free onSpirit Organics, ~~November~~LLC 5(FSO), ~~2014,~~American inEducation ~~addition~~Consulting toGroup, MrRaymond C. Dabney ~~being~~University a(RCDU), ~~controlling~~American States University and ~~shareholder~~Royalty ofManagement ~~the~~Services ~~Company~~Corp. ~~since~~(RMS) ~~September~~to ~~2009~~lease and adevelop ~~10.78%~~250 ~~equity~~Acres ~~interest~~of land located in ~~OmniCanna~~Holt, ~~since~~California ~~June~~for ~~2013~~15 years. ~~Benjamin~~As ~~Tam~~a master facilitator, ~~CFO~~the ~~and director~~Company ~~and~~will ~~Robert~~provide ~~Kane~~general support with developing, ~~COO~~cultivating and ~~director~~processing ofIndustrial Hemp for RCDU and FSO on the ~~Company~~property. ~~are~~Pursuant ~~also~~to the ~~CFO~~agreement, the Company and ~~director~~RMS are responsible for a $400,000 non-refundable deposit and ~~COO~~the development and ~~director~~operations ofon ~~Omnicanna~~the property on 50-50 basis. ~~Therefore~~ Additionally, the Company ~~was~~will ~~deemed~~share to40% ~~have~~of ~~significant~~net ~~influence~~profit as investor with RMS and ~~control~~retain 5% of ~~OmniCanna~~net ~~Health~~profit ~~Solutions,~~as ~~Inc~~master facilitator.

On November 5, 2014, the Company recorded $247,500 in marketable securities and $85,277 (based on currency converted as of March 31, 2017) in loans to OmniCanna and to its equity method investee account in accordance with ASC 323. An unrealized gain on the equity method account of $52,500 was recognized for the three months ended March 31, 2017 in addition to a unrealized gain on the equity method investee account of $144,000 was recognized for the year ended December 31, 2016 in the value of Omnicanna marketable securities.

			Accumulated		June 30, 2017		December 31, 2016
	Cost		Depletion		Net Book Value		Net Book Value
Property Farming Rights
Fort McDermit Allottees Land	$	50,000	$	3,889	$	46,111	$	47,778
Washoe Tribal Allotment Lands		640,000		13,852		626,148		638,948
Winnemucca Tribal MBS Lands		200,000		1,571		198,429		0
		890,000	$	19,312		870,688		686,726
Operating capital for Washoe Lands	$	85,000			$	85,000	$	—
Operating capital for Winnemucca Lands		93,500		—		93,500		65,000
	$	178,500	$	—		178,500		65,000
Total	$	1,068,500	$	19,312	$	1,049,188	$	751,726

10All equipment is stated at cost. Maintenance ~~GOODWILL~~and repairs are charged to expense as incurred and ~~INTANGIBLE~~the ~~ASSETS~~cost of renewals and betterments are capitalized. Depreciation is computed using the straight-line method over the estimated lives of the related assets, 2 years for computer, 2 years for software, 5 years for equipment and laboratory equipment and 3 years for automobile.

	March 31, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(499,049	)		(488,299	)
Less: Impairment of Goodwill		(170,689	)		(170,689	)
Total intangible assets, net	$	161,250		$	172,000

All property farm rights are amortized over the term of each respective agreements.

~~Intangible assets are stated at fair value on the date of purchase less accumulated amortization~~9. ~~Amortization is computed using the straight-line method over the estimated lives of the~~ ~~related~~ EQUITY ~~assets~~METHOD ~~(5 years for both intellectual assets and Goodwill).~~ INVESTEE

~~F-14~~On November 5, 2014, the Company accounted for its investment and loans in OmniCanna Health Solutions, Inc. (formerly Endocan Corporation) using the equity method pursuant to ASC 323 – Investments – Equity Method and Joint Ventures. In accordance with ASC 323, when the Company does not have a controlling financial interest in an entity but exerts significant influence over the entity’s operating and financial policies, the Company accounts for its investment in accordance with the equity method of accounting. This generally applies to cases in which the Company owns a voting or economic interest of between 20 and 50 percent.

11The accounting using the equity method is in conjunction with appointment of Raymond Dabney as CEO and director of the Company on November 5, 2014, in addition to Mr. ~~PREPAID~~Dabney ~~EXPENSES~~being ~~AND~~a ~~DEPOSITS~~controlling ~~HELD~~shareholder ~~WITH~~of ~~RMS~~the Company since September 2009 and a 10.78% equity interest in OmniCanna since June 2013. Benjamin Tam, CFO and director and Robert Kane, COO and director of the Company are also the CFO and director and COO and director of Omnicanna. Therefore, the Company was deemed to have significant influence and control of OmniCanna Health Solutions, Inc.

On October 1, 2016, the Company entered a Paying Agent Agreement with Royalty Management Services Corp. (RMS) for holding funds and making payment for expenses and commitments of the Company. The Company has entered a Management Agreement with RMS since September 15 2016 for management, investors’ and shareholders’ communications, website development, database management, accounting and management of all activities such as travel and conference. All the expenses related to the services for the Company are included as part of the management fees.F-14

~~March~~On November 315, 2014, the Company recorded $247,500 in marketable securities and $85,277 (based on currency converted as of June 30, 2017) in loans to OmniCanna and to its equity method investee account in accordance with ASC 323. An unrealized gain on the equity method account of $52,500 was recognized for the six months ended June 30, 2017 in addition to a unrealized gain on the equity method investee account of $144,000 was recognized for the year ended December 31, 2016 in the value of Omnicanna marketable securities.

Prepaid consulting expenses	$	138,000	$	141,750
Prepaid Legal fees		90,000		90,000
Prepaid rent		244		244
Prepaid management fees		47,500
Deposits held with RMS		—		576,520
Total Prepaid expenses and Deposits held with RMS	$	275,744	$	808,514

10. GOODWILL and INTANGIBLE ASSETS

12. COMMITMENTS


	June 30, 2017			December 31, 2016
Intellectual assets, primarily intellectual property	$	660,299		$	660,299
Goodwill		170,688			170,688
Less: accumulated amortization		(509,799	)		(488,299	)
Less: Impairment of Goodwill		(170,688	)		(170,688	)
Total intangible assets, net	$	150,500		$	172,000

~~The~~Intangible assets ~~Company~~are ~~has~~stated ~~lease~~at ~~commitments~~fair ~~for~~value ~~its~~on ~~European~~the ~~operations under~~date ~~private~~of ~~companies,~~purchase ~~MLS~~less ~~Lap~~accumulated Bamortization.V. ~~and~~Amortization ~~MJR~~is ~~B.V.~~computed ~~owned~~using ~~and~~the ~~controlled~~straight-line method byover ~~Mario~~the ~~Lap,~~estimated ~~director~~lives of the ~~Company~~related ~~and~~assets ~~director~~(5 ~~and officer~~years offor EUboth ~~subsidiaries.~~intellectual ~~Negotiations~~assets ~~are ongoing in regards to preparing finalized agreements between the Company~~ and MrGoodwill). ~~Lap’s companies.~~

1311. ~~SUBSEQUENT~~ PREPAID ~~EVENTS~~EXPENSES AND DEPOSITS HELD WITH RMS

On October ~~April 18~~1, ~~2017~~2016, the Company ~~issued~~ ~~10,000,000~~entered ~~shares~~a ~~S-8~~Paying ~~registered~~Agent ~~free-trading~~Agreement ~~common~~with ~~stock~~Royalty ~~under~~Management anServices ~~Option~~Corp. ~~Agreement~~(RMS) for holding funds and making payment for expenses and commitments of ~~2016~~the ~~Equity~~Company. ~~Award~~The ~~Plan~~Company Bhas entered a Management Agreement with ~~exercise~~RMS since September ~~price~~15 at2016 ~~$0.02~~for management, investors’ and ashareholders’ ~~fair~~communications, ~~market~~website ~~value~~development, ofdatabase ~~$829~~management,~~000~~ toaccounting and ~~Chief~~management ~~Medical~~of ~~Officer,~~all Dractivities such as travel and conference. ~~Allen~~All ~~Herman~~the expenses related to the services for the Company are included as part of the management fees.

OnJune ~~April 27~~30, 2017, ~~the~~December Company entered a five-year Research Collaboration Agreement with DFCI for a research project to develop and investigate the use of Cannabinolds to cure various forms of cancer and investigate synergies with radiotherapy and immunotherapy. In consideration for this agreement and performance of the research31, the Company is obligated to pay DFCI a total of $1,834,062 over the life of the agreement with $159,287 due at signing and $418,683 to be paid at each anniversary of the agreement for the next four years.2016

On May 8, 2017, the Company issued 7,000,000 shares of R144 restricted common stock with a fair market value of $469,000 pursuant to a one-year consulting agreement.

Prepaid consulting expenses	$	134,250	$	141,750
Prepaid Legal fees		—		90,000
Prepaid rent		244		244
Prepaid management fees		37,500		—
Deposits held with RMS		241,015		576,520
Deposit for acquisition of Jinvator		65,214		—
Total Prepaid expenses and Deposits held with RMS	$	478,223	$	808,514

~~On May 10, 2017, the Company paid €60,000 to the principal shareholder of Jinvator BioMed GmbH (Jinvator) as deposit for the purchase of the 74~~12.~~9 % equity~~ ~~interest in Jinvator.~~COMMITMENTS

OnThe Company ~~May~~has ~~17,~~lease ~~2017~~commitments for its European operations under private companies, ~~the~~MLS ~~Company~~Lap ~~issued~~B.V. and MJR B.V. owned and controlled 1by Mario Lap,~~500,000~~ ~~shares~~director of ~~R144~~the ~~restricted~~Company ~~common~~and ~~stock~~director ~~with~~and aofficer ~~fair~~of ~~market~~EU ~~value~~subsidiaries. ofNegotiations ~~$93,600~~are ~~pursuant~~ongoing in regards to apreparing finalized ~~one-year~~agreements ~~consulting~~between ~~agreement~~the Company and Mr. Lap’s companies.

F-15

~~On May 18, 2017, the Company entered an Exclusive Master Facilitator Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit Organics, LLC (FSO), American Education Consulting Group, Raymond C~~13. ~~Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to~~ ~~lease~~ SUBSEQUENT and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and retain 5% of net profit as master facilitator.EVENTS

On August ~~May 31~~3, 2017, ~~$375,000~~the inCompany ~~Accounts~~issued ~~Payable for management fees accumulated from January 1~~10, ~~2017 to May 31~~000,000 ~~2017~~shares ~~was~~S-8 ~~settled~~registered ~~by issuance of a one~~free-~~year~~trading ~~Convertible~~common ~~Promissory~~stock ~~Note~~under toan ~~Royalty Management~~Option ~~Services~~Agreement ~~Corp. At the election~~ of ~~the~~2016 Equity ~~note~~Award ~~holder,~~Plan itB ~~can~~with beexercise ~~converted~~price ~~into common stock of the Company~~ at ~~the par value of~~ $0.~~001~~015 and a ~~share~~fair ormarket ~~other~~value ~~mutually agreed upon price. The Company has fully recognized the conversion discount~~ of ~~the Note as prepaid interest to the maximum amount of~~ $~~375~~471,000 into ~~accordance~~a ~~with ASC 470-20-30-8 and amortize it over the life of the Note~~consultant.

FOn August 10, 2017, the Company issued 10,000,000 shares S-168 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 and a fair market value of $425,000 to a consultant pursuant to a consulting agreement

~~ITEM~~On August 2.10, ~~MANAGEMENT’~~2017, the Company issued 10,000,000 shares S-8 ~~DISCUSSION~~registered ~~AND~~free-trading ~~ANALYSIS~~common OFstock ~~FINANCIAL~~under ~~CONDITION~~an ~~AND~~Option ~~RESULTS~~Agreement OFof ~~OPERATIONS~~2016 Equity Award Plan B with exercise price at $0.03 and a fair market value of $425,000 to a consultant.

~~This section of this report includes~~On aAugust ~~number of forward-looking statements that reflect our current views with respect to future events and financial performance. Forward-looking statements are often identified by words like: believe~~16, ~~expect~~2017, ~~estimate,~~the ~~anticipate,~~Company ~~intend,~~issued ~~project and similar expressions~~25, ~~or words which~~000,000 byshares ~~their~~S-8 ~~nature,~~registered ~~refer to future events. You should not place undue certainty on these forward~~free-~~looking~~trading ~~statements,~~common ~~which~~stock ~~apply~~to ~~only~~a asconsultant ofpursuant ~~the~~to ~~date~~a ~~of this report. These forward~~two-~~looking~~year consulting ~~states~~agreement ~~are~~dated ~~subject~~August to10, ~~certain risks~~2017 ~~and~~under ~~uncertainties~~2016 ~~that~~Equity ~~could~~Award ~~cause~~Plan ~~actual~~B ~~results~~with toa ~~differ~~fair ~~materially~~market ~~from~~value ~~historical~~of ~~results or our predictions~~$1,062,500.

~~Overview of the Company’s Business~~F-16

~~Cannabis Science, Inc. (formerly Gulf~~ITEM ~~Onshore, Inc~~2.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. OnMANAGEMENT’S ~~June~~DISCUSSION 6,AND ~~2007,~~ANALYSIS ~~the~~OF ~~Company~~FINANCIAL ~~changed~~CONDITION ~~its~~AND ~~name~~RESULTS ~~from~~OF National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.OPERATIONS

~~Cannabis~~This section ~~Science,~~of ~~Inc.~~this isreport atincludes ~~the~~a ~~forefront~~ number of ~~medical~~forward-looking ~~cannabis~~statements ~~research~~that ~~and~~reflect ~~development. The~~our ~~Company~~current ~~works~~views with ~~world~~respect ~~authorities~~to onfuture ~~phytocannabinoid~~events and ~~science~~financial ~~targeting critical~~performance. Forward-looking ~~illnesses,~~statements ~~and~~are ~~adheres~~often toidentified ~~scientific~~by ~~methodologies~~words tolike: ~~develop~~believe, ~~produce~~expect, estimate, anticipate, intend, project and ~~commercialize~~similar ~~phytocannabinoid-based~~expressions, ~~pharmaceutical products. In~~or ~~summary~~words which, weby ~~are~~their ~~dedicated~~nature, refer to ~~the~~future ~~creation~~events. You ofshould ~~cannabis~~not place undue certainty on these forward-~~based~~looking ~~medicines~~statements, ~~both~~which ~~with~~apply ~~and~~only ~~without~~as ~~psychoactive~~of ~~properties,~~the date of this report. These forward-looking states are subject to ~~treat~~certain ~~disease~~risks and ~~the~~uncertainties ~~symptoms~~that ofcould ~~disease,~~cause asactual ~~well~~results asto ~~for~~differ ~~general~~materially ~~health~~from ~~maintenance~~historical results or our predictions.

~~Cannabis Science, Inc., takes advantage~~Overview of ~~its~~the ~~unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. The~~ Company’s works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.Business

Cannabis Science, Inc. ~~takes~~(formerly ~~advantage~~Gulf Onshore, Inc.) (“We” or “the Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its ~~unique~~name ~~understanding~~to ofNational ~~metabolic~~Healthcare ~~processes~~Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to ~~provide~~Brighton ~~innovative~~Oil ~~treatment~~& ~~options~~Gas, ~~for~~Inc., ~~unmet~~and ~~medical~~converted ~~needs~~to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 7, 2009, the Company changed its name to Cannabis Science, Inc.

Cannabis Science, ~~use~~Inc. ~~has~~is anat ~~extensive~~the ~~history~~forefront of medical cannabis research and development. The Company works with world authorities ~~dating~~on ~~back~~phytocannabinoid ~~thousands~~science oftargeting ~~years~~critical illnesses, and ~~currently~~adheres ~~there~~to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In summary, we are ~~thousands~~dedicated to the creation of ~~peer~~cannabis-~~reviewed~~based ~~scientific~~medicines, both ~~publications~~with ~~that~~and ~~document~~without psychoactive properties, to treat disease and the ~~underlying biochemical~~symptoms ~~pathways~~of ~~that~~disease, ~~cannabinoids~~as ~~modulate~~well as for general health maintenance.

At Cannabis Science, weInc., ~~use~~takes anadvantage ~~inquiring approach~~of toits ~~discover~~unique ~~and~~understanding ~~develop~~of metabolic processes to provide novel ~~cannabinoid-based~~treatment ~~therapies~~approaches to ~~improve~~a ~~patients’~~number of ~~lives~~illnesses for which current treatments and understanding remain unsatisfactory. The ~~From~~Company ~~the~~works ~~initiation,~~with ~~our~~leading ~~founders~~experts ~~have~~in ~~been~~drug ~~committed~~development, tomedicinal ~~fostering~~characterization, and ~~maintaining~~clinical aresearch ~~bold~~to develop, ~~pioneering~~produce, ~~spirit~~and ~~fostering~~commercialize ~~the~~novel ~~true~~therapeutic approaches ~~nature~~for ofthe ~~innovation~~treatment ~~from~~for ~~which~~illnesses ~~cutting edge~~caused ~~ideas~~by ~~flourish~~infections ~~and~~as ~~translate~~well ~~into~~as ~~evidence~~for age-~~based~~related ~~solutions~~illness. Our initial focus is on skin cancers and neurological conditions.

~~We are dedicated to working closely~~Cannabis ~~with local~~Science, ~~national~~Inc. ~~and~~takes ~~international~~advantage ~~regulatory~~of ~~agencies~~its tounique ~~provide~~understanding ~~access~~of tometabolic ~~high~~processes ~~quality, first class cannabinoid pharmaceuticals~~ to ~~those~~provide ~~critically~~innovative intreatment ~~need~~options ~~of new treatments~~ for ~~life threatening and debilitating conditions. Cannabis Science’s clinical~~unmet ~~trial~~medical ~~material comes from the cultivation and production facilities that are GMP compliant, surpassing high quality standard industrial and food processing requirements~~needs.

~~The~~Cannabis use ~~Company~~has ~~works~~an ~~with~~extensive ~~leading~~history ~~experts in~~dating ~~drug~~back ~~development,~~thousands ~~medicinal~~of ~~characterization~~years, and ~~clinical~~currently ~~research~~there toare ~~develop,~~thousands ~~produce,~~of ~~and~~peer-reviewed ~~commercialize~~scientific ~~novel therapeutic~~publications ~~approaches~~that ~~for~~document the ~~treatment~~underlying ofbiochemical ~~multiple~~pathways ~~critical~~that ~~ailments~~cannabinoids ~~from cancer and infections to age-related illnesses~~modulate.

~~Our~~At Cannabis ~~products~~Science, ~~broadly~~we ~~described,~~use ~~are medical~~an ~~cannabinoid~~inquiring ~~formulations~~approach ~~developed~~to ~~from~~discover ~~one~~and ordevelop ~~more~~novel ofcannabinoid-based ~~the~~therapies ~~cannabinoid~~to ~~compounds~~improve ~~found~~patients’ lives. inFrom the ~~cannabis~~initiation, ~~plant.~~our ~~Our~~founders ~~immediate focus~~have isbeen committed to ~~treat~~fostering ~~one~~and ofmaintaining a bold, pioneering spirit fostering the ~~most~~true ~~important~~nature ~~diseases~~of ininnovation ~~the~~from ~~world,~~which ~~cancer~~cutting edge ideas flourish and translate into evidence-based solutions.

~~CS-S/BCC1~~We are isdedicated into ~~preparation~~working closely with local, national and international regulatory agencies to ~~enter phase~~provide Iaccess ~~clinical~~to ~~trials~~high ~~within~~quality, first ~~one~~class cannabinoid pharmaceuticals to ~~two~~those ~~year.~~critically ~~This~~in ~~product~~need isof ~~formulated~~new treatments for ~~topical~~life ~~administration~~threatening toand bedebilitating ~~tested~~conditions. Cannabis inScience’s ~~phase~~clinical Itrial ~~study~~material comes from the cultivation and production facilities that are GMP compliant, ~~with~~surpassing anhigh ~~indication~~quality ~~for~~standard ~~skin~~industrial ~~cancer~~and food processing requirements.

4The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment of multiple critical ailments from cancer and infections to age-related illnesses.

~~CS-TATI1 is in preclinical development~~Our ~~with~~products, ~~the~~broadly ~~indication~~described, ~~for~~are ~~infectious~~medical ~~disease. Consistent~~cannabinoid ~~with~~formulations ~~data~~developed ~~published~~from inone ~~March~~or bymore ~~researchers~~of at the ~~Mount~~cannabinoid ~~Sinai~~compounds ~~School~~found ofin ~~Medicine~~the ~~found~~cannabis ~~that~~plant. ~~cannabinoids~~Our ~~inhibit~~immediate ~~TAT~~focus ~~induced~~is ~~migration~~ to ~~TAT~~treat ~~via~~one ~~cannabinoid~~of 2the ~~receptors~~most ~~(CB2)~~important ~~which~~diseases ~~has potential applications~~ in ~~HIV~~the ~~and~~world, ~~other infectious diseases~~cancer.

~~In November 2013, Cannabis Science submitted~~CS-S/BCC1 ~~patent~~is ~~application N2010968~~ in ~~Europe~~preparation ~~entitled~~to ~~"Composition~~enter ~~for~~phase ~~the~~I ~~Treatment~~clinical oftrials ~~Neurobehavioral~~within ~~Disorders." The subject~~one ~~of the patent is development of cannabinoid-based formulations~~ to ~~treat~~two ~~a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety~~year. ~~The~~This ~~first~~product ~~formulation~~is informulated ~~the~~for ~~series~~topical ~~of neurobehavioral disorder-targeted~~administration ~~products~~to isbe ~~the~~tested ~~pre-clinical development and use of the invention~~ in ~~food~~phase ~~products~~I ~~through~~study, ~~a licensing agreement~~ with aan ~~strategic partner~~indication ~~and~~for ~~related~~skin ~~company, OmniCanna Health Solutions, Inc~~cancer. ~~And Cannabis Science will move forward at the same time with pharmaceutical grade product development.~~

~~Cannabis plants have extensive history of medical and agricultural use dating back thousands of years.~~4

ToCS-TATI1 is ~~date~~in ~~hundreds~~preclinical ofdevelopment ~~natural~~with ~~constituents covering~~the ~~several~~indication ~~chemical~~for ~~classes~~infectious ~~have~~disease. Consistent ~~been~~with ~~isolated~~data ~~and~~published ~~identified~~in ~~from~~March by researchers at the ~~Cannabis~~Mount ~~plant~~Sinai School of Medicine found that cannabinoids inhibit TAT induced migration to TAT via cannabinoid 2 receptors (CB2) which has potential applications in HIV and other infectious diseases.

~~Some~~In November ~~key~~2013, ~~phytocannabinoids~~Cannabis ~~are:~~Science submitted patent application N2010968 in Europe entitled "Composition for the Treatment of Neurobehavioral Disorders." The subject of the patent is development of cannabinoid-based formulations to treat a variety of neurobehavioral disorders, such as attention deficit hyperactivity disorder (ADHD) and anxiety. The first formulation in the series of neurobehavioral disorder-targeted products is the pre-clinical development and use of the invention in food products through a licensing agreement with a strategic partner and related company, OmniCanna Health Solutions, Inc. And Cannabis Science will move forward at the same time with pharmaceutical grade product development.

·Cannabis plants ~~etrahydrocannabinol~~have ~~(THC)~~extensive history of medical and agricultural use dating back thousands of years.

·To date ~~cannabidiol~~hundreds ~~(CBD)~~of natural constituents covering several chemical classes have been isolated and identified from the Cannabis plant.

·Some key ~~cannabigerol~~phytocannabinoids ~~(CBG)~~are:

· ~~cannabichromene~~tetrahydrocannabinol (~~CBC~~THC)

· ~~cannabinol~~cannabidiol (~~CBN~~CBD)

~~These~~· ~~cannabinoids~~cannabigerol ~~belong to the chemical class of terpenophenolics, of which 85 have been uniquely identified in cannabis, including the most psychoactive cannabinoid, THC.~~ (CBG)

~~Some~~· ~~applications~~cannabichromene of cannabinoids have been well established in peer-reviewed literature such as for alleviating nausea and stimulating the appetite for people with AIDS and cancer. Other well-known uses include easing chronic pain and reducing muscle spasms associated with multiple sclerosis and spinal cord injuries.(CBC)

~~The~~· ~~pharmacology~~cannabinol of THC has been widely studied, while many other identified cannabinoids are still poorly characterized pharmacologically and biologically, with new activities for cannabinoids consistently being discovered.(CBN)

~~Cannabis Science is developing novel~~These ~~cannabis~~cannabinoids ~~based~~belong ~~approaches~~ to ~~treat~~ the ~~world’s~~chemical ~~most~~class ~~deadly~~of ~~illnesses.~~terpenophenolics, Weof ~~learn~~which ~~from~~85 ~~patients~~have ~~about~~been ~~the~~uniquely ~~healing~~identified ~~properties of~~in cannabis, ~~medicines. Our immediate focus is~~ including the ~~development~~most ofpsychoactive ~~cutting~~cannabinoid, ~~edge cancer treatments~~THC.

~~The~~Some applications ~~Company’s~~of ~~future~~cannabinoids ~~endeavors include~~have ~~infectious~~been ~~illnesses,~~well ~~neurobehavioral~~established ~~disorders~~in ~~including~~peer-reviewed ~~attention~~literature ~~deficit~~such ~~disorder,~~as ~~post-traumatic~~for ~~stress~~alleviating ~~disorder;~~nausea and stimulating anthe ~~application~~appetite offor ~~the~~people ~~anti~~with AIDS and cancer. Other well-~~inflammatory~~known ~~activities~~uses ofinclude ~~cannabis~~easing inchronic ~~the~~pain ~~management~~and ofreducing ~~age-related~~muscle ~~illnesses~~spasms associated with multiple sclerosis and spinal cord injuries.

The pharmacology ~~endocannabinoid~~of ~~system~~THC ~~possessed by~~has ~~all~~been ~~vertebrates~~widely ~~regulates~~studied, ~~all~~while ~~body~~many ~~systems~~other ~~and~~identified ~~maintains~~cannabinoids ~~homeostasis.~~are Asstill ~~such~~poorly characterized pharmacologically and biologically, ~~the~~with ~~mechanisms~~new ofactivities ~~phytocannabinoids’~~for ~~biological impact~~cannabinoids ~~are~~consistently ~~multidimensional~~being discovered.

5Cannabis Science is developing novel cannabis based approaches to treat the world’s most deadly illnesses. We learn from patients about the healing properties of cannabis medicines. Our immediate focus is the development of cutting edge cancer treatments.

~~While concentrating on our core activities~~The ~~of discovering and developing treatments that will make a meaningful difference in patients~~Company’s ~~lives,~~future weendeavors ~~remain~~include ~~mindful~~infectious ~~that we have other responsibilities to the clinicians who utilize our drugs~~illnesses, ~~health~~neurobehavioral ~~authorities~~disorders ~~around~~including ~~the~~attention ~~world,~~deficit ~~our shareholders~~disorder, ~~our~~post-traumatic ~~employees,~~stress ~~and~~disorder; ~~the communities in which we live~~ and ~~work. We~~an ~~continually~~application ~~strive~~of tothe ~~improve~~anti-inflammatory ~~our corporate responsibility standards and~~ activities, ~~implementing~~of ~~comprehensive~~cannabis ~~ethical~~in ~~standards~~the ~~and~~management ~~undertaking~~of ~~patient and community progressive initiatives~~age-related illnesses.

~~These~~The endocannabinoid ~~principles~~system ~~reflect~~possessed ~~the~~by ~~mission of~~all ~~Cannabis~~vertebrates ~~Science~~regulates toall ~~provide~~body ~~innovative~~systems ~~therapeutics~~and ~~for~~maintains ~~unmet~~homeostasis. ~~medical~~As ~~needs~~such, the mechanisms of phytocannabinoids’ biological impact are multidimensional.

AsWhile concentrating ~~the~~on ~~industry~~our ~~leader,~~core ~~Cannabis~~activities ~~Science consults~~of discovering and ~~leads~~developing ~~other~~treatments ~~emerging~~that ~~businesses~~will make a meaningful difference in patients’ lives, we remain mindful that ~~Cannabis~~we ~~Science~~have ~~believes~~other ~~has~~responsibilities ato ~~preferred~~the ~~business~~clinicians ~~model,~~who ~~one~~utilize ~~which~~our ~~will~~drugs, ~~mature~~health authorities around ~~into~~the aworld, ~~key~~our ~~business~~shareholders, ~~model~~our inemployees, and the ~~future.~~communities ~~Our~~in ~~consulting~~which iswe onlive ~~the~~and ~~entire~~work. We ~~"seed~~continually strive to ~~sale"~~improve our ~~process~~corporate ~~with~~responsibility astandards ~~focus~~and onactivities, ~~bio-pharmaceutical~~implementing comprehensive ethical standards and undertaking patient and ~~development~~community progressive initiatives.

~~Cannabis Science is one of the longest~~These ~~standing~~principles ~~companies~~reflect in the ~~cannabis~~mission ~~business. We~~of ~~feel~~Cannabis ~~that~~Science ~~the correct way is~~ to ~~look~~provide atinnovative ~~the~~therapeutics ~~industry~~for ~~from~~unmet amedical ~~bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based products to modulate the endocannabinoid system to treat multiple conditions~~needs.

On March 30, 2009, the Company entered into an agreement with Cannex Therapeutics, LLC, (“Cannex”) a California limited liability company, and its principal, medical cannabis pioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The asset purchase agreement includes all of Cannex’s and Kubby’s intellectual property rights, formulas, patents, trademarks, client base, hardware and software, including the website www.phytiva.com. The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to Cannex, and K & D transferred 8,500,000 shares to Cannex and others. A Form 8-K reflecting this transaction was timely filed. 5

As ~~part of the Agreement, on April 1,~~ ~~2009,~~ the ~~Company~~industry ~~appointed Mr. Kubby as President and CEO~~leader, ~~Richard~~Cannabis ~~Cowan~~Science asconsults ~~Director~~ and ~~CFO,~~leads ~~and~~other ~~Robert~~emerging ~~Melamede~~businesses ~~Ph.~~that ~~D.,~~Cannabis ~~as Director and Chief~~ Science ~~Officer. Each~~believes ofhas ~~them was also appointed as~~ a ~~director. All of the Company’s current directors~~preferred ~~then~~business ~~resigned. On April 7~~model, ~~2010,~~one ~~the~~which ~~Company~~will ~~changed~~mature ~~its~~into ~~name to Cannabis Science, Inc., and obtained~~ a ~~new~~key ~~CUSIP~~business ~~number. Its shares~~model ~~now~~in ~~trade under~~ the ~~symbol CBIS~~future.~~OB. A~~ ~~Form~~Our ~~8-K~~consulting ~~was~~is ~~timely~~on ~~filed, with a copy of~~ the ~~Asset~~entire ~~Acquisition~~"seed ~~Agreement~~to sale" ~~and~~process ~~Board~~with ~~Resolution~~a ~~ratifying~~focus ~~the~~on ~~Agreement~~bio-pharmaceutical ~~provided as exhibits thereto~~development.

~~On April 7, 2009, the Company changed its name to~~ Cannabis Science, ~~Inc., reflecting its new business mission: Cannabis Science, Inc.~~ is atone ~~the forefront~~ of ~~medical marijuana~~the ~~research~~longest ~~and~~standing ~~development. The~~companies ~~Company~~in works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the ~~creation of~~ cannabis~~-based~~ ~~medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance~~business. ~~The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.~~

OnWe feel ~~May~~that 7,the ~~2009,~~correct way is to look at the ~~Company~~industry ~~common~~from ~~shares~~a bio-pharmaceutical standpoint, in a manner that allows cannabinoid-based ~~commenced~~products ~~trading~~to ~~under~~modulate the ~~new~~endocannabinoid ~~stock~~system ~~symbol~~to ~~OTC:~~treat ~~CBIS~~multiple conditions.

~~The~~On March 30, 2009, the Company ~~formed~~entered ~~two~~into ~~operating~~an ~~subsidiaries~~agreement ~~Cannabis~~with ~~Science~~Cannex Therapeutics, LLC, (“Cannex”) a California limited BVliability company, and ~~Cannabis~~its ~~Science~~principal, ~~International~~medical ~~Holding~~cannabis BVpioneer and entrepreneur Steven W. Kubby, to acquire all of their interest in certain assets used to conduct a cannabis research and development business. The ~~Netherlands~~asset onpurchase ~~May~~agreement ~~10th~~includes all of Cannex’s and ~~May~~Kubby’s ~~6th~~intellectual property rights, ~~2013~~formulas, ~~respectively~~patents, trademarks, client base, hardware and software, including the website www.phytiva.com. The Company and its largest shareholder, K & D Equities, Inc., exchanged a total of 10,600,000 shares of common stock for the assets of Cannex; the Company issued 2,100,000 shares to ~~pursue~~Cannex, and ~~business~~K ~~opportunities~~& inD ~~Europe~~transferred 8,500,000 shares to Cannex and ~~worldwide~~others. A Form 8-K reflecting this transaction was timely filed.

~~There are minimal operating activities~~As inpart of the ~~subsidiaries~~Agreement, ason ofApril ~~March 31~~1, ~~2017~~2009,~~. Mario~~ ~~Lap,~~the aCompany ~~director~~appointed ofMr. ~~the~~Kubby ~~Company~~as President and ~~director~~CEO, ~~and~~Richard ~~officer~~Cowan ~~its~~as ~~European~~Director ~~subsidiaries,~~and isCFO, ~~conducting~~and ~~various~~Robert ~~business~~Melamede ~~activities~~Ph. ofD., ~~the~~as ~~Company~~Director inand ~~Spain~~Chief ~~under~~Science ~~his~~Officer. Each ~~personal~~of ~~name~~them ~~and/or~~was ~~his~~also ~~personal~~appointed ~~holding~~as ~~companies~~a ~~MLS Lap B~~director.~~V.,~~ All ~~MJR~~of ~~B.V.~~the ~~and~~Company’s ~~Cannabis~~current ~~Agency~~directors Bthen resigned.V. On ~~until~~April ~~such~~7, ~~time~~2010, as the Company changed isits ~~able~~name to ~~establish~~Cannabis aScience, ~~Spanish~~Inc., ~~subsidiary~~and toobtained ~~conduct its~~a ~~own~~new ~~business~~CUSIP ~~operations~~number. Its ~~and~~shares ~~activities,~~now ~~including~~trade ~~but~~under ~~not~~the ~~limited~~symbol CBIS.OB. A ~~to:~~Form ~~operating~~8-K ~~lease~~was ~~for~~timely ~~farms~~filed, ~~asset~~with ~~purchases,~~a ~~office~~copy ~~and equipment,~~of ~~personnel~~the ~~employment~~Asset ~~and~~Acquisition ~~other~~Agreement ~~business~~ and ~~operating~~Board ~~activities~~Resolution ratifying asthe ~~may~~Agreement beprovided ~~required~~as ~~from~~exhibits ~~time-to-time~~thereto.

6On April 7, 2009, the Company changed its name to Cannabis Science, Inc., reflecting its new business mission: Cannabis Science, Inc. is at the forefront of medical marijuana research and development. The Company works with world authorities on phytocannabinoid science targeting critical illnesses, and adheres to scientific methodologies to develop, produce, and commercialize phytocannabinoid-based pharmaceutical products. In sum, we are dedicated to the creation of cannabis-based medicines, both with and without psychoactive properties, to treat disease and the symptoms of disease, as well as for general health maintenance. The Company obtained a new CUSIP number as well. Cannabis Science Inc. has also launched its new website www.cannabisscience.com reflecting its new name.

On ~~August 6, 2014, the Company signed~~ aMay ~~proposal letter with Michigan Green Technologies~~7, ~~LLC (“MGT”) to acquire an additional 30.1% equity in MGT that would increase the Company’s equity ownership to 50.1%. As consideration for acquiring the additional 30.1% equity~~2009, the Company ~~issued~~ acommon ~~total of twenty million (20,000,000)~~ shares tocommenced ~~the~~trading ~~principals~~under ~~and shareholders of MGT over 12 months (see Form 8-K with~~ the ~~SEC~~new onstock ~~file~~symbol ~~no.~~OTC: ~~000-28911 August 8, 2014)~~CBIS.

~~On January 5, 2015 the~~ The Company ~~announced~~formed ~~the~~two ~~International release~~operating ofsubsidiaries 8Cannabis ~~initial~~Science ~~products~~BV ~~that will be synergistically produced, distributed~~ and ~~marketed across the Netherlands, Spain and California where~~ Cannabis Science isInternational ~~active~~Holding ~~and~~BV ~~has~~in ~~cannabis production facilities.~~ The ~~products are currently ready for pre-clinical~~Netherlands ~~studies,~~on ~~self-medicating~~May ~~patient~~10th ~~ailment~~and ~~usage,~~May ~~marketing~~6th ~~release~~, ~~sales and distribution. The company also released The Cannabis Science Patient Access Center (PAC) http://pac.cannabisscience.com~~2013, ~~in beta version~~respectively, isto ~~now~~pursue ~~available~~business ~~for~~opportunities ~~patients~~in toEurope ~~track usage~~ and ~~receive updates~~worldwide.

OnThere are ~~May~~minimal 7,operating ~~2015~~activities in the ~~Company~~subsidiaries ~~announced~~as ~~the~~of ~~Assets acquisition~~June of30, ~~Equi-Pharm~~2017,. Mario ~~LLC~~Lap, a ~~USA~~director ~~manufacturer and distributor~~ of ~~specialty~~the ~~horse~~Company and ~~pet grooming~~ director and ~~topical applications.~~officer ~~The~~its ~~acquisition~~European ~~incorporates~~subsidiaries, anis ~~extensive~~conducting ~~expansion~~various ~~plan~~business ~~for~~activities ~~Equi-Pharm~~of ~~including~~the ~~"Large~~Company ~~Animal"~~in ~~such as~~Spain ~~horses,~~under ~~cattle,~~his ~~sheep~~personal name and/or ~~the~~his ~~like~~personal ~~and~~holding ~~"Small~~companies ~~Animal"~~MLS orLap ~~"Pets" include cats~~B.V., ~~dogs,~~MJR ~~pet~~B.V. ~~snakes~~ and ~~the like~~Cannabis ~~for~~Agency ~~medical and cosmetic products~~B.V. Asuntil ~~consideration~~such ~~for~~time ~~acquiring~~as the ~~Assets,~~Company ~~which~~is ~~consist~~able ofto establish ~~Inventory,~~a ~~Trademark~~Spanish ~~and brand~~subsidiary ~~names,~~to ~~and~~conduct ~~goodwill,~~its ~~the~~own ~~Company~~business ~~issued~~operations ~~ten~~and ~~million (10~~activities,~~000,000)~~ ~~shares~~including tobut ~~the~~not ~~shareholders~~limited ~~of Equi-Pharm and agreed~~ to: operating ~~change~~lease ~~its~~for ~~company~~farms, ~~name.~~asset ~~The~~purchases, ~~acquisition~~office ~~was~~and ~~completed on November 16~~equipment, ~~2015~~personnel employment and ~~the~~other ~~Company~~business ~~has~~and ~~formed~~operating aactivities ~~new~~as ~~wholly owned~~may ~~subsidiary~~be ~~called~~required ~~Equi-Pharm~~from ~~LLC. The Company is working closely with management of Equi~~time-~~Pharm~~ to ~~expand the product lines~~-time.

On August ~~May~~6, 192014, ~~2015~~the ~~Cannabis~~Company ~~Science~~signed ~~announced~~a ~~the~~proposal ~~expansion of~~letter ~~licensing~~with ~~deal~~Michigan ~~with~~Green ~~Purple~~Technologies, ~~Haze~~LLC ~~Properties~~(“MGT”) to acquire an additional 30.1% ~~Cannabis~~equity ~~Science~~in ~~and~~MGT ~~Purple~~that ~~Haze~~would ~~Properties~~increase ~~are~~the ~~working~~Company’s ~~together~~equity ownership to ~~launch~~50.1%. As ~~exciting~~consideration for acquiring the ~~lines~~additional of30.1% ~~quality~~equity, ~~cannabis~~the ~~products~~Company ~~using~~issued ~~scientific~~a ~~genetics~~total ~~and~~of ~~creating~~twenty anmillion ~~education~~(20,000,000) ~~platform~~shares to ~~share~~the ~~information~~principals ~~from~~and ~~doctors~~shareholders of ~~and~~MGT ~~patients~~over ~~around~~12 ~~the~~months ~~world~~(see ~~about~~Form 8-K with the ~~advances~~SEC ofon ~~cannabis~~file ~~research~~no. 000-28911 August 8, 2014).

On January ~~May 27~~5, 2015 the Company announced athe ~~Historic~~International ~~Collaborative Drug~~release ~~Development~~of ~~deal~~8 ~~with~~initial ~~IGXBio~~products ~~and~~that ~~its~~will ~~GenePro®,~~be asynergistically ~~DNA-based~~produced, ~~immunotherapeutic~~distributed and ~~that~~marketed ~~recently~~across ~~received~~the ~~FDA~~Netherlands, ~~IND~~Spain ~~approval~~and ~~to enter~~California ~~into~~where ~~human~~Cannabis ~~trials.~~Science ~~The~~is ~~companies~~active ~~intend~~and tohas ~~develop~~cannabis aproduction ~~joint~~facilities. The ~~protocol~~products toare ~~demonstrate~~currently ~~potential~~ready ~~synergistic~~for ~~effects~~pre-clinical ofstudies, ~~their respective~~self-medicating ~~drug~~patient ~~candidates~~ailment inusage, ~~HIV~~marketing release, assales ~~well~~and distribution. asThe ~~potential~~company ~~new~~also ~~drug~~released ~~candidates.~~The ~~IGXBio~~Cannabis isScience aPatient ~~privately~~Access ~~held~~Center ~~clinical~~(PAC) ~~stage~~http://pac.cannabisscience.com, ~~biotechnology~~in beta ~~company~~version, ~~developing~~is ~~advanced~~now ~~DNA~~available ~~immunotherapies~~ for ~~HIV~~patients ~~infection,~~to ~~based~~track inusage ~~Fairway,~~and ~~KS,~~receive ~~USA~~updates.

On July 16, 2015 Cannabis Science announced guidance in regards to its State-by-State initiatives, including its new product releases. On the forefront are the California new product releases. The Company has signed a research and distribution agreement with Cannabis Science Research Foundation (CSRF). The CSRF will be responsible for the release and distribution of the CBIS products for its initial State-by-State initiatives in California. The CSRF distribution agreement is due to the committed focus CBIS has on its federal drug development program. As a result of this new agreement with CSRF the Cannabis Science Patient Access Center will be moved to the CSRF website as well.6

On May ~~November 2~~7, 2015, the Company announced athe ~~significant collaborative~~Assets ~~drug~~acquisition ~~development~~of ~~deal~~Equi-Pharm ~~with IGXBio Inc.~~LLC, ~~and~~a ~~its~~USA ~~GenePro®,~~manufacturer aand ~~DNA-based~~distributor ~~immunotherapeutic~~of ~~that~~specialty ~~recently received~~horse ~~FDA~~and ~~IND~~pet ~~approval~~grooming toand ~~enter~~topical ~~into human trials~~applications. The ~~companies~~acquisition ~~developed~~incorporates ~~joint~~an ~~protocols~~extensive ~~that~~expansion ~~explore~~plan ~~potential~~for ~~synergistic~~Equi-Pharm ~~effects~~including "Large ofAnimal" ~~their~~such ~~respective~~as ~~drug~~horses, ~~candidates~~cattle, assheep ~~well~~and asthe ~~potential~~like ~~new~~and ~~drug~~"Small ~~candidate~~Animal" ~~opportunities.~~or ~~IGXBio~~"Pets" ~~has~~include acats, ~~drug called GenePro®~~dogs, pet ~~which~~snakes isand ~~already~~the ~~registered~~like ~~with~~for ~~the~~medical ~~FDA~~ and ~~has~~cosmetic anproducts. ~~IND~~As ~~number.~~consideration ~~This~~for ~~expedites~~acquiring the ~~process~~Assets, towhich ~~seek~~consist ~~FDA~~of ~~approval~~Inventory, Trademark inand ~~the~~brand ~~future. GenePro®~~names, isand ~~designed~~goodwill, tothe ~~promote~~Company anissued ~~anti-HIV~~ten ~~immune~~million ~~response~~(10,000,000) ~~that~~shares ~~facilitates~~to ~~virus~~the ~~control~~shareholders inof ~~HIV~~Equi-~~infected subjects. There~~Pharm ~~are~~and ~~more~~agreed ~~than~~to ~~150~~change ~~peer-reviewed~~its ~~publications~~company ~~that describe the effectiveness of GenePro®~~name. The ~~inflammatory~~acquisition ~~response~~was ~~that~~completed ~~is associated~~on ~~with~~November ~~HIV~~16, ~~infection~~2015 isand ~~present~~the atCompany ~~even~~has ~~low~~formed ~~levels of viral replication, and is~~ a ~~major~~new ~~causal factor for the morbidities~~wholly ~~and~~owned ~~associated~~subsidiary ~~mortality~~called ofEqui-Pharm ~~HIV infection~~LLC. ~~Low-grade~~The ~~inflammation~~Company ~~frequently occurs despite clinically successful anti-retroviral therapy and~~ is ~~associated~~working closely with ~~increased~~management ~~incidence~~ of ~~heart~~Equi-Pharm ~~disease,~~to ~~bone~~expand ~~disease,~~the ~~and~~product ~~cancers~~lines.

On May ~~November 11~~19, 2015, Cannabis Science announced the ~~release~~ expansion of ~~seven~~licensing ~~original~~deal ~~cannabinoid-based~~with ~~animal~~Purple ~~care~~Haze Properties. Cannabis Science and Purple Haze Properties are working together to launch exciting lines of quality cannabis products ~~through~~using ~~its~~scientific ~~wholly~~genetics ~~owned~~and ~~subsidiary,~~creating an ~~Equi-Pharm,~~education ~~LLC~~platform to share information from doctors and patients around the world about the advances of cannabis research.

7On May 27, 2015 the Company announced a Historic Collaborative Drug Development deal with IGXBio and its GenePro®, a DNA-based immunotherapeutic that recently received FDA IND approval to enter into human trials. The companies intend to develop a joint protocol to demonstrate potential synergistic effects of their respective drug candidates in HIV, as well as potential new drug candidates. IGXBio is a privately held clinical stage biotechnology company developing advanced DNA immunotherapies for HIV infection, based in Fairway, KS, USA.

On July ~~November 25~~16, 2015, ~~the Company announced positive results from its initial test run of its Pure Decarboxylated CO2 Oil (PDCO) released through the~~ Cannabis Science ~~Research~~announced ~~Foundation~~guidance ~~(CSRF or~~in ~~the~~regards ~~Foundation)~~ to 15its ~~dispensaries and several less fortunate self~~State-~~medicating patients. This trial, collaborative rollout~~ by ~~CSRF, as contracted by Cannabis Science to the California not~~-~~for-profit~~State initiatives, ~~was~~including ~~designed~~its tonew ~~meet~~product ~~two primary goals~~releases. ~~The first, to~~ ~~conduct~~On ~~tests on~~ the ~~efficacy~~forefront ofare the ~~product~~California ~~for~~new ~~patients;~~product ~~the~~releases. ~~second,~~The toCompany ~~gather~~has ~~proprietary~~signed ~~data~~a ~~based~~research onand ~~testimonials~~distribution ~~from~~agreement ~~real~~with Cannabis ~~self-medicating~~Science ~~consumers~~Research ~~from~~Foundation ~~their firsthand experiences~~(CSRF). The ~~feedback~~CSRF ~~received~~ will be ~~used~~responsible tofor ~~influence~~ the ~~Company's~~release ~~continuing efforts~~and todistribution ~~bring~~of the ~~best~~CBIS ~~cannabinoid-based~~products ~~formulations~~for ~~to market On November 30, 2015 Cannabis Science announced the launch of~~its ~~their~~initial ~~cannabinoid~~State-~~formulated~~by-State ~~capsule~~initiatives ~~product~~in ~~line~~California. The ~~initial~~CSRF ~~capsule~~distribution ~~formulations~~agreement ~~released~~is ~~are~~due ~~CBD,~~to ~~Indica, and Sativa; each of~~ the ~~three~~committed ~~types~~focus ofCBIS ~~caps~~has ~~will~~on beits federal ~~available~~drug indevelopment ~~25mg,~~program. ~~50mg,~~As ~~and~~a ~~100mg~~result ~~doses~~of ~~and~~this ~~will~~new beagreement ~~provided~~with inCSRF ~~two-dose~~the ~~packs~~Cannabis ~~with~~Science ~~more~~Patient ~~size options~~Access toCenter will be ~~made~~moved ~~available~~to in the ~~near~~CSRF ~~future~~website as well.

On November ~~December 10~~2, 2015, the Company announced ~~that~~a ~~Cannabis Science~~significant ~~entered~~collaborative ~~Select~~drug development deal with IGXBio Inc., ~~New~~and ~~High~~its GenePro®, a DNA-~~Dosage~~based ~~product~~immunotherapeutic ~~line~~that recently received FDA IND approval to enter into human trials. The companies developed joint protocols that explore potential synergistic effects of ~~CBD~~their respective drug candidates, ~~Sativa~~as well as potential new drug candidate opportunities. IGXBio has a drug called GenePro®, which is already registered with the FDA and ~~Indica~~has ~~Capsules~~an ~~into~~IND number. This expedites the ~~Industry-Famous~~process ~~Emerald~~to ~~Cup~~seek ~~Event~~FDA approval in the future. GenePro® is designed to promote an anti-HIV immune response that facilitates virus control in ~~Santa~~HIV-infected ~~Rosa~~subjects. There are more than 150 peer-reviewed publications that describe the effectiveness of GenePro®. The inflammatory response that is associated with HIV infection is present at even low levels of viral replication, CAand onis ~~December~~a ~~12th~~major causal factor for the morbidities and ~~13th~~associated mortality of HIV infection. Low-grade inflammation frequently occurs despite clinically successful anti-retroviral therapy and is associated with increased incidence of heart disease, bone disease, and cancers.

On November ~~December 15~~11, 2015 ~~after successful formulation work~~, Cannabis Science ~~follows~~announced ~~through~~the ~~with~~release aof ~~full~~seven ~~clinical~~original ~~drug development agreement with ImmunoClin to deliver GMP quality pre~~cannabinoid-~~clinical~~based ~~data~~animal tocare ~~enter~~products ~~CS-NEURO-1~~through ~~into a Phase I human study in Europe. After ImmunoClin successfully completed~~ its ~~one-year~~wholly ~~formulation~~owned ~~work for CBIS~~subsidiary, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality preEqui-~~clinical data~~Pharm, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in EuropeLLC.

On November ~~March 24~~25, ~~2016~~2015, the Company ~~entered~~announced apositive 15results ~~years~~from ~~Joint~~its ~~Venture License~~initial ~~Agreement~~test ~~with~~run ~~the Ft.~~of ~~McDermitt~~its ~~Allotment~~Pure ~~land~~Decarboxylated ~~Allotees,~~CO2 ~~which~~Oil is(PDCO) released onthrough the ~~Ft.~~Cannabis ~~McDermitt~~Science ~~Tribal~~Research ~~Reservation,~~Foundation ~~Raymond C.~~(CSRF ~~Dabney~~or ~~University,~~the ~~American~~Foundation) ~~Education~~to ~~Consulting~~15 ~~Group~~dispensaries and ~~Cannabis~~several ~~Science,~~less ~~Inc~~fortunate self-medicating patients. ~~for~~This atrial, ~~total~~collaborative ofrollout ~~ten~~by ~~(10)~~CSRF, ~~one~~as ~~(1)~~contracted ~~acre~~by ~~parcels of~~Cannabis ~~land.~~Science ~~The~~to ~~project~~the isCalifornia not-for-profit, was designed to ~~benefit~~meet ~~both~~two ~~the~~primary Ftgoals. ~~McDermitt~~The ~~Tribe and Members~~first, ~~and~~to ~~Allotment~~conduct ~~Allottees.~~tests ~~Cannabis~~on ~~Science made~~the anefficacy ~~initial payment~~ of ~~$50,000~~the product for ~~farming~~ ~~rights~~patients; ~~and initial development of~~ the ~~first~~second, ~~two~~to gather ~~one~~proprietary ~~(1)~~data ~~acre~~based ~~parcel~~on oftestimonials ~~land located~~from inreal ~~Fort~~self-medicating ~~McDermitt~~consumers ~~Tribal~~from ~~Reservation~~their infirsthand ~~the~~experiences. ~~State~~The offeedback received ~~Nevada,~~will ~~USA. Each~~be ~~one~~used ~~(1)~~to ~~acre~~influence ~~parcel~~the ofCompany's ~~land~~continuing isefforts ~~specifically designated~~to ~~for~~bring ~~placement~~the nobest ~~more~~cannabinoid-based ~~than~~formulations ~~twelve~~to ~~(12)~~market On ~~three~~November (330,~~000)~~ ~~square~~2015 ~~foot~~Cannabis ~~greenhouses~~Science ~~for~~announced the ~~production~~launch of ~~Cannabis~~their ~~and~~cannabinoid-formulated ~~all Cannabis~~capsule ~~related~~product ~~products~~line. ~~All~~ ~~harvested~~The ~~products~~initial ~~are~~capsule formulations toreleased beare ~~delivered~~CBD, Indica, and ~~sold~~Sativa; toeach ~~qualified licensed~~of ~~distribution~~the ~~centers. The~~three ~~Company~~types isof tocaps ~~share~~will ~~40%~~be ofavailable ~~the~~in ~~Adjust~~25mg, ~~Gross~~50mg, ~~Income~~and ~~after~~100mg doses ~~deduction~~and ofwill ~~related~~be ~~operating~~provided ~~expenses~~in ~~and~~two-dose ~~cost~~packs with more size options to ~~build~~be made available in the ~~green houses~~near future.

On December ~~October 24~~10, ~~2016~~2015, the Company ~~entered an~~announced ~~Exclusive~~that ~~Master~~Cannabis ~~Facilitator~~Science ~~Agreement~~entered ~~with Members of Winnemucca Tribal Allotment~~Select, ~~Free~~New ~~Spirit~~High-Dosage ~~Organics,~~product ~~LLC,~~line ~~American~~of ~~Education Consulting Group and Raymond C. Dabney University to provide general support with developing~~CBD, ~~cultivating and processing of Cannabis/Hemp on 320 Acres of leased land in Humboldt County~~Sativa, ~~Nevada. The Company’s share is 40% of net profit derived from the sale~~ and ~~distribution~~Indica ofCapsules ~~Cannabis/Hemp~~into ~~products grown and manufactured on these lands. Under~~ the ~~agreement,~~Industry-Famous ~~the~~Emerald ~~Company~~Cup ~~will~~Event bein ~~provided one~~Santa ~~(1) acre of land for research and development with placement of no more than 36~~Rosa,~~000~~ ~~square~~CA ~~feet~~on ofDecember ~~greenhouses~~12th ~~used for cultivation~~ and ~~research of Cannabis/Hemp~~13th. ~~The term of this Exclusive Master Agreement is five (5) years and up to twenty-five (25) years.~~

On November 12, 2016, the Company entered an Exclusive Master Facilitator Agreement with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of leased land located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years. On December 21, 2016, the Company paid $40,000 to the property owner under the agreement for the one (1) acre of land.7

8On December 15, 2015 after successful formulation work, Cannabis Science follows through with a full clinical drug development agreement with ImmunoClin to deliver GMP quality pre-clinical data to enter CS-NEURO-1 into a Phase I human study in Europe. After ImmunoClin successfully completed its one-year formulation work for CBIS, focusing on cannabis extracts and cannabinoids, the results are compelling and conclusive. ImmunoClin will, under its class I license, initiate, manage, and coordinate all aspects of the new comprehensive clinical research program on behalf of Cannabis Science. The new program will focus on delivering compliant GMP quality pre-clinical data, including cultivation of CBIS specific cannabis strains, formulation and manufacturing of clinical grade material to enable entry of CS-NEURO-1 and other cannabinoid based products into a Phase I human studies in Europe.

On March ~~December 18~~24, 2016, the Company ~~enter six~~entered ~~(6)~~a ~~Exclusive~~15 ~~Master~~years ~~Facilitator~~Joint ~~Agreement~~Venture ~~for~~License ~~cultivation~~Agreement ~~of Medical Marijuana/Hemp~~ with the Ft. ~~Members~~McDermitt ofAllotment ~~Washoe~~land ~~Tribal Allotments~~Allotees, inwhich ~~Douglas~~is ~~County,~~on ~~Nevada,~~the ~~together~~Ft. ~~with~~McDermitt ~~Free~~Tribal ~~Spirit Organics~~Reservation, ~~LLC, American Education Consulting Group and~~ Raymond C. Dabney University to, ~~provide~~American ~~general~~Education ~~support~~Consulting ~~with~~Group ~~developing, cultivating~~ and ~~processing~~ Cannabis~~/Hemp~~ Science, ~~with~~Inc. ~~Free~~for ~~Spirit~~a ~~Organics,~~total ~~LLC~~of onten 13(10), one (1) acre ~~parcel~~parcels of ~~leased~~ land,. ~~Lot~~The 1,project 2,is 3,designed 4,to 5,benefit 7,both ~~8, 9, 10, 11, 12, 13 and 14, located in~~ the ~~allotment~~Ft. ~~cc183, a portion of the~~McDermitt SETribe ¼and ~~of section 15~~Members, ~~township~~and 11Allotment ~~North,~~Allottees. ~~Range~~Cannabis ~~21,~~Science ~~East~~made ~~Mount~~an ~~Diablo~~initial ~~Meridian,~~payment ~~Douglas County~~ of ~~Nevada. The Family Allotment will receive~~ $4050,000 ~~per~~for farming ~~acre~~rights ~~Good~~and ~~Faith Non-Refundable Deposit per~~ initial development ~~site.~~of ~~The~~the ~~Company’s~~first ~~share~~two isone ~~20%~~(1) onacre ~~all~~parcel ~~initial non-refundable~~of ~~deposits~~land ~~from~~located ~~external~~in ~~investor,~~Fort ~~and~~McDermitt ~~10%~~Tribal ofReservation ~~net~~in ~~profit derived from~~ the ~~sale~~State ~~and distribution~~ of ~~Cannabis/Hemp products~~Nevada, ~~grown and manufactured on the land~~USA. Each ~~Under the agreement, the Company will be provided~~ one (1) acre parcel of land ~~for~~is ~~research~~specifically ~~and~~designated ~~development with~~for placement of no more than 36twelve (12) three (3,000) square foot ~~feet of~~ greenhouses ~~used~~ for ~~cultivation~~the ~~and~~production ~~research~~ of Cannabis~~/Hemp.~~ ~~The~~and ~~term~~all ~~of this~~Cannabis ~~Exclusive~~related ~~Master~~products. All ~~Agreement~~harvested isproducts ~~twenty-five~~are ~~(25)~~to ~~years~~be ~~renewable~~delivered and ~~every~~sold ~~five~~to ~~(5)~~qualified licensed ~~years~~distribution centers. OnThe ~~December~~Company ~~23,~~is ~~2016,~~to ~~the~~share ~~Company~~40% ~~paid $100,000~~of to the ~~property~~Adjust ~~owner~~Gross ~~members~~Income ~~under~~after ~~the~~deduction of ~~agreements~~related ~~and~~operating ~~record~~expenses ~~the~~and ~~unpaid~~cost ~~balance~~to ofbuild ~~$420,000~~the ingreen ~~accounts payable~~houses.

On October ~~December 21~~24, 2016, the Company ~~enter~~ ~~two~~entered ~~(2)~~an Exclusive Master Facilitator Agreement ~~for cultivation of Medical Marijuana/Hemp~~ with ~~the~~ Members of ~~Washoe~~ Winnemucca Tribal ~~Allotments in Douglas County~~Allotment, ~~Nevada, together with~~ Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing of Cannabis/Hemp ~~with Free Spirit Organics, LLC~~ on ~~two~~320 ~~(2)~~Acres ~~one (1) acre parcel~~ of leased land, ~~Lot 6 and 21, located~~ in ~~the~~Humboldt ~~allotment cc183~~County, ~~a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of~~ Nevada. The ~~Family~~ ~~Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The~~ Company’s ~~share~~ share is 2040% ~~on all initial non-refundable deposits from external investor, and 10%~~ of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on ~~the~~these ~~land~~lands. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is ~~twenty-five (25) years renewable~~ ~~every~~ five (5) years. Onand ~~December~~up ~~23, 2016, the Company paid a total of $45,000~~ to ~~the~~twenty-five ~~two~~(25) ~~property owners under the agreements and recorded the unpaid balance of $35,000 in accounts payable~~years.

On November ~~January 3~~12, ~~2017~~2016, the Company entered a ~~Research~~an ~~Collaboration~~Exclusive Master Facilitator Agreement with ~~Dana-Farber~~the ~~Cancer~~Members ~~Institute~~of Washoe Tribal Allotments in Douglas County, ~~Inc~~Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on Lot 20, one (1) acre parcel of ~~Boston~~leased ~~Massachusetts~~land ~~for~~located in the allotment cc183, a ~~research~~portion ~~project~~of tothe ~~develop~~SE ¼ of section 15, township ~~and~~11 ~~investigate~~North, ~~the~~Range ~~use~~21, East Mount Diablo Meridian, Douglas County of ~~Cannabinolds~~Nevada. toThe ~~cure~~Company’s ~~various~~share ~~caner~~is 20% on all initial non-refundable deposits from external investor, and ~~investigate~~10% ~~synergies~~of ~~with~~net ~~radiotherapy~~profit derived from the sale and ~~immunotherapy~~distribution of Cannabis/Hemp products grown and manufactured on the land. InUnder the agreement, the Company will be provided one (1) acre of land for research and development ~~consideration~~with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement ~~and~~is ~~performance~~twenty-five of(25) ~~the~~years ~~Research~~renewable every five (5) years. On December 21, 2016, the Company ~~has~~ paid $~~201~~40,~~656~~000 to ~~Dana-Farber~~the ~~Cancer~~property ~~Institute, Inc~~owner under the agreement for the one (1) acre of land.

On December ~~February 2~~18, ~~2017~~2016, the ~~Cannabis~~Company ~~Science GmbH,~~enter asix ~~subsidiary~~(6) ~~90%~~Exclusive ~~owned~~Master byFacilitator Agreement for cultivation of Medical Marijuana/Hemp with the ~~Company~~Members ~~and~~of ~~10%~~Washoe ~~owned~~Tribal byAllotments ~~Dupetit~~in ~~Natural~~Douglas ~~Products~~County, ~~GmbH~~Nevada, ~~has~~together ~~entered~~with aFree ~~Share~~Spirit ~~Purchase~~Organics, LLC, ~~Agreement~~American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with ~~Jinvator~~Free ~~BioMed~~Spirit ~~GmbH~~Organics, LLC on 13 one (~~Jinvator~~1) acre parcel of leased land, Lot 1, 2, 3, 4, 5, 7, 8, 9, 10, 11, 12, 13 and 14, located in the allotment cc183, a ~~German~~portion ~~corporation~~of the SE ¼ of section 15, ~~for~~township 11 74North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada.9 The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the ~~total~~sale ~~issued~~and distribution of Cannabis/Hemp products grown and ~~outstanding~~manufactured ~~shares~~on the land. Under the agreement, the Company will be provided one (1) acre of ~~Jinvator~~land for research and ~~three~~development ~~hundred~~with ~~thousand~~placement ~~Euros~~of (€no ~~300~~more than 36,000) ~~which~~square ~~has~~feet aof USgreenhouses ~~dollar~~used ~~equivalent~~for ofcultivation ~~$324,300~~and research of Cannabis/Hemp. The ~~acquisition~~term of this Exclusive Master Agreement is ~~pending~~twenty-five on(25) ~~verifications~~years renewable every five (5) years. On December 23, 2016, the Company paid $100,000 to the property owner members under the agreements and record the unpaid balance of ~~key~~$420,000 ~~information~~in accounts payable.

The Company is working on several business acquisition and development projects to increase business and revenue generation in 2017 and beyond, including but not limited to: product licensing and royalty agreements, private label hemp product line, consulting, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in 2017.8

~~Liquidity~~On December 21, 2016, the Company enter two (2) Exclusive Master Facilitator Agreement for cultivation of Medical Marijuana/Hemp with the Members of Washoe Tribal Allotments in Douglas County, Nevada, together with Free Spirit Organics, LLC, American Education Consulting Group and Raymond C. Dabney University to provide general support with developing, cultivating and processing Cannabis/Hemp with Free Spirit Organics, LLC on two (2) one (1) acre parcel of leased land, Lot 6 and 21, located in the allotment cc183, a portion of the SE ¼ of section 15, township 11 North, Range 21, East Mount Diablo Meridian, Douglas County of Nevada. The Family Allotment will receive $40,000 per acre Good Faith Non-Refundable Deposit per development site. The Company’s share is 20% on all initial non-refundable deposits from external investor, and 10% of net profit derived from the sale and distribution of Cannabis/Hemp products grown and manufactured on the land. Under the agreement, the Company will be provided one (1) acre of land for research and development with placement of no more than 36,000 square feet of greenhouses used for cultivation and research of Cannabis/Hemp. The term of this Exclusive Master Agreement is twenty-five (25) years renewable every five (5) years. On December 23, 2016, the Company paid a total of $45,000 to the two property owners under the agreements and recorded the unpaid balance of $35,000 in accounts payable.

~~The Company has a working capital deficit~~On ofJanuary $43,~~050,319~~ ~~as of March 31,~~ 2017, ~~compared~~the toCompany entered a ~~working~~Research ~~capital~~Collaboration ~~deficit~~Agreement ofwith ~~$2,983,206~~Dana-Farber asCancer ~~of December 31~~Institute, ~~2016,~~Inc. ~~There~~of ~~are~~Boston ~~insufficient~~Massachusetts ~~liquid~~for ~~assets~~a toresearch ~~meet~~project ~~current~~to ~~liabilities~~develop ~~or sustain operations through 2016~~ and ~~beyond~~investigate ~~and~~ the ~~Company~~use ~~must~~of ~~raise~~Cannabinolds ~~additional capital~~ to ~~cover~~cure ~~the~~various ~~working~~caner, ~~capital~~and ~~deficit.~~investigate ~~Management~~synergies iswith radiotherapy ~~working~~and onimmunotherapy. ~~plans~~In toconsideration ~~raise~~for ~~additional~~this ~~capital~~Agreement ~~through private placements~~ and ~~lending~~ ~~facilities. The~~performance ~~Company~~of ~~currently~~the isResearch, ~~relying~~the onCompany ~~existing~~has ~~cash~~paid ~~and loans from stockholders~~ $201,656 to ~~meet~~Dana-Farber ~~its~~Cancer ~~obligations and~~Institute, ~~sustain operations~~Inc.

~~The~~On February ~~Company~~2, ~~has~~2017, ~~promissory~~the ~~note~~Cannabis ~~payment commitments~~Science ~~of $1~~GmbH,~~340,156~~ ~~due~~a tosubsidiary ~~stockholders~~90% ~~and~~owned ~~currently~~by isthe inCompany ~~default. The~~and ~~Company~~10% isowned ~~negotiating~~by ~~with~~Dupetit ~~the~~Natural ~~debtors~~Products toGmbH, ~~extend~~has ~~the~~entered ~~notes~~a ~~payable.~~Share InPurchase ~~addition~~Agreement with Jinvator BioMed GmbH (Jinvator), ~~the~~a ~~Company~~German ~~has~~corporation, ~~convertible~~for ~~promissory~~74.9% ~~notes~~of ~~payment~~the ~~commitment~~total issued and outstanding shares of ~~$670,407~~Jinvator tofor ~~Raymond~~three ~~C. Dabney~~hundred thousand Euros (€ 300,000) ~~CEO/Director~~which ofhas ~~the~~a ~~Company~~US ~~and~~dollar equivalent of $~~860~~324,~~790~~300. The toacquisition ~~Royalty~~is ~~Management~~pending ~~Services~~on ~~Corp~~verifications of key information.

On May 10, 2017, the Company paid €60,000, which has a US dollar equivalent of $65,214, to the principal shareholder of Jinvator BioMed GmbH (Jinvator) as deposit for the purchase of the 74.9 equity interest in Jinvator.

~~Contractual~~On April ~~Obligations~~27, 2017, the Company entered a five-year Research Collaboration Agreement with DFCI for a research project to develop and investigate the use of Cannabinolds to cure various forms of cancer and investigate synergies with radiotherapy and immunotherapy. In consideration for this agreement and performance of the research, the Company is obligated to pay DFCI a total of $1,834,062 over the life of the agreement with $159,287 due at signing and $418,683 to be paid at each anniversary of the agreement for the next four years.

~~The~~On May 18, 2017, the Company ~~has~~entered ~~various~~an ~~commitments~~Exclusive ~~under~~Master ~~consulting~~Facilitator ~~contracts~~Agreement with Winnemucca Tribal MBS of Nevada, Free Spirit ~~debt~~Organics, ~~settlement~~LLC (FSO), ~~farming~~American ~~rights~~Education ~~agreements~~Consulting Group, ~~laboratory~~Raymond ~~services~~C. Dabney University (RCDU), American States University and Royalty Management Services Corp. (RMS) to lease and develop 250 Acres of land located in Holt, California for 15 years. As a master facilitator, the Company will provide general support with developing, cultivating and processing Industrial Hemp for RCDU and FSO on the property. Pursuant to the agreement, ~~joint~~the Company and RMS are responsible for a $400,000 non-refundable deposit and the development and operations on the property on 50-50 basis. Additionally, the Company will share 40% of net profit as investor with RMS and ~~joint~~retain ~~venture~~5% ~~agreement~~of net profit as master facilitator.

~~Capital~~ The Company ~~Resources~~is working on several business acquisition and development projects to increase business and revenue generation in 2017 and beyond, including but not limited to: product licensing and royalty agreements, private label hemp product line, consulting, and other strategic acquisitions to support product development, production, and distribution of newly acquire or manufactured cannabis and hemp based products. There can be no assurance that these will be successful in generating revenues in 2017.

The Company has additional capital resource requirements for personnel, supplies, research and development, laboratory, cultivation equipment, green houses and scientific equipment of approximately $6,000,000 over the next 12 months. These capital disbursements are dependent on management’s successful raising of capital through private placements and/or lending facilities.9

The Company is not currently in good short-term financial standing. We anticipate that we may only generate limited revenues in the near future and we will not have enough positive internal operating cash flow until we can generate substantial revenues, which may take the next two years to fully realize. There is no assurance we will achieve profitable operations. We have historically financed our operations primarily by cash flows generated from the sale of our equity securities and through cash infusions from officers and outside investors in exchange for debt and/or common stock.Liquidity

~~Results~~The Company has a working capital deficit of ~~Operations~~$4,670,849 as of June 30, 2017, compared to a working capital deficit of $2,983,206 as of December 31, 2016, There are insufficient liquid assets to meet current liabilities or sustain operations through 2016 and beyond and the Company must raise additional capital to cover the working capital deficit. Management is working on plans to raise additional capital through private placements and lending facilities. The Company currently is relying on existing cash and loans from stockholders to meet its obligations and sustain operations.

~~For~~The Company ~~the~~has ~~three~~promissory ~~months~~note ~~ended~~payment ~~March~~commitments 31of $1,340,156 ~~2017~~due ~~(“2017”)~~to stockholders and currently is in default. The Company asis ~~compared~~negotiating with the debtors to extend the ~~prior~~notes ~~year~~payable. ~~three~~In ~~months~~addition, ~~ended~~the ~~March~~Company 31has convertible promissory notes payment commitment of $670,407 ~~2016~~to ~~(“2016”):~~Raymond C. Dabney, CEO/Director of the Company and $1,235,790 to Royalty Management Services Corp.

~~The Company had $3,733 in revenues for~~Contractual ~~the 2017 compared to $2,925 for 2016. This increase in revenue is due to assets acquisition of Equi-Pharm and license revenue from product sales.~~Obligations

~~Our~~The Company ~~research~~has ~~and~~various ~~development~~commitments ~~expenses increased~~under byconsulting ~~$53~~contracts,~~943~~ todebt ~~$216~~settlement,~~943~~ ~~for~~farming ~~the~~rights ~~three~~agreements, ~~months~~laboratory ~~ended~~services ~~March 31~~agreement, joint ~~2017 compared to $163~~development,~~000~~ ~~for~~and ~~the~~joint ~~three~~venture ~~months ended March 31, 2016~~agreement.

~~Our unrealized gain on equity investee~~Capital ~~decreased by $16,500 to $52,500 for the three months ended March 31, 2017 compared to $69,000 for the three months ended March 31, 2016.~~Resources

~~Net~~The Company ~~loss~~has onadditional ~~settlement~~capital ofresource ~~debt~~requirements ~~decreased by~~for ~~$588~~personnel,~~645~~ tosupplies, $0research ~~for~~and ~~the~~development, ~~three~~laboratory, ~~months~~cultivation equipment, ~~ended~~green ~~March~~houses ~~31,~~and ~~2017~~scientific ~~compared~~equipment toof approximately $~~588~~6,~~645~~000,000 ~~for~~over the ~~three~~next 12 months. These ~~ended~~capital ~~March~~disbursements are ~~31,~~dependent ~~2016~~on management’s successful raising of capital through private placements and/or lending facilities.

~~General~~The Company ~~and~~is ~~administrative~~not ~~expenses increased~~currently byin ~~$1,008,816~~good toshort-term ~~3,400,505~~financial ~~for~~standing. We anticipate that we may only generate limited revenues in the ~~three~~near ~~months~~future ~~ended~~and ~~March~~we ~~31,~~will ~~2017~~not ~~compared~~have toenough $2positive internal operating cash flow until we can generate substantial revenues,~~391,689~~ which ~~for~~may take the ~~three~~next ~~months~~two ~~ended March~~years ~~31,~~to ~~2016~~fully realize. ~~This~~There ~~increase~~is ~~was~~no ~~due~~assurance towe ~~higher~~will ~~share~~achieve ~~prices~~profitable inoperations. We have historically financed our operations primarily by cash flows generated from the ~~stock~~sale ~~compensation~~of ~~expense~~our ~~pursuant~~equity tosecurities ~~management~~and ~~consulting~~through cash infusions from officers and ~~bonus~~outside ~~agreements~~investors in exchange for debt and/or common stock.

~~The Company is working on several~~Results ~~business development projects to generate revenues, including: investing in the cultivation~~ of leased properties with Members of the Washoe Tribal Allotment, Winnemucca Tribal Allotment, HRM Farm and Free Spirit Organics, LLC in Nevada and California that will generate increased license, royalty revenue, Cannabis/Hemp products sales, and other strategic acquisitions to support product development, production, and distribution of newly acquired or manufactured cannabis and hemp based products. The Company’s drug development through its laboratory services to facilitate new inhalation study for asthma/COPD and other respiratory conditions. In addition, the Company signed an agreement with Equi-Pharm for the commercialization of pet products for distribution in California. Notwithstanding, there can be no assurance that these will be successful in generating revenues in 2017.Operations

~~ITEM~~For the 3.six ~~QUANTITATIVE~~months ~~AND~~ended ~~QUALITATIVE~~June ~~DISCLOSURES~~30, ~~ABOUT~~2017 ~~MARKET~~(“2017”) ~~RISK~~as compared to the prior year six months ended June 30, 2016 (“2016”):

~~Not~~The Company ~~applicable~~had $3,985 in revenues for the 2017 compared to $5,787 for 2016. This decrease in revenue was due to reduction of sales of Equi-Pharm and license revenue from product sales.

10Our research and development expenses increased by $127,295 to $385,832 for the six months ended June 30, 2017 compared to $258,537 for the six months ended June 30, 2016.

~~ITEM~~Our unrealized 4.loss ~~CONTROLS~~on ~~AND~~equity ~~PROCEDURES~~investee increased by $51,750 to $51,750 for the six months ended June 30, 2017 compared to $0 for the six months ended June 30, 2016.

~~Our Chief Executive Officer and Chief~~Net ~~Financial~~loss ~~Officer,~~on ~~after~~settlement ~~evaluating the effectiveness~~ of ~~our~~debt ~~disclosure~~decreased ~~controls~~by ~~and~~$588,645 ~~procedures~~to ~~(as~~$0 ~~defined~~for ~~in Rule 13a-15(e) and 15d-15(e) under~~ the ~~Exchange~~six ~~Act)~~months asended ofJune ~~the~~30, ~~end~~2017 ofcompared ~~the~~to ~~period covered by this report~~$588,645 ~~have~~for ~~concluded that, based on~~ the ~~evaluation~~six ofmonths ~~these~~ended ~~controls~~June ~~and procedures~~30, ~~that our disclosure controls and procedures were not effective~~2016.

~~There~~General and ~~were~~administrative noexpenses ~~changes~~increased inby ~~our~~$1,351,688 ~~internal controls~~to or$5,132,856 infor ~~other~~the ~~factors~~six ~~during~~months ~~the~~ended ~~last~~June ~~fiscal~~30, ~~quarter~~2017 ~~covered~~compared byto ~~this~~$3,781,168 for ~~report~~the ~~that~~six ~~have~~months ~~materially~~ended ~~affected~~June 30, or2016. This ~~are~~increase ~~likely~~ was due to ~~materially~~higher ~~affect~~share prices in the ~~Company’s~~stock ~~internal~~compensation ~~controls~~expense ~~over~~pursuant to ~~financial~~management ~~reporting~~consulting and bonus agreements.

~~PART II OTHER INFORMATION~~10

~~ITEM~~The Company 1is working on several business development projects to generate revenues, including: investing in the cultivation of leased properties with Members of the Washoe Tribal Allotment, Winnemucca Tribal Allotment, HRM Farm and Free Spirit Organics, LLC in Nevada and California that will generate increased license, royalty revenue, Cannabis/Hemp products sales, and other strategic acquisitions to support product development, production, and distribution of newly acquired or manufactured cannabis and hemp based products. The ~~BUSINESS~~Company’s drug development through its laboratory services to facilitate new inhalation study for asthma/COPD and other respiratory conditions. In addition, the Company signed an agreement with Equi-Pharm for the commercialization of pet products for distribution in California. Notwithstanding, there can be no assurance that these will be successful in generating revenues in 2017.

~~CAUTIONARY~~ITEM 3. QUANTITATIVE ~~STATEMENT~~AND ~~REGARDING~~QUALITATIVE ~~FORWARD-LOOKING~~DISCLOSURES ~~INFORMATION~~ABOUT MARKET RISK

~~This Interim Report on Form 10-Q~~Not contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statementsapplicable. Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the forward-looking statements are reasonable as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.

~~Readers should carefully review and~~ITEM consider the various disclosures made by us in this Report, set forth in detail in Part I, under the heading “Risk Factors,” as well as those additional risks described in other documents we file from time to time with the Securities and Exchange Commission, which attempt to advise interested parties of the risks, uncertainties, and other factors that affect our business4. WeCONTROLS ~~undertake no~~AND obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.PROCEDURES

AsOur Chief ~~used~~Executive inOfficer ~~this~~and ~~Form~~Chief ~~10-Q~~Financial Officer, after evaluating the ~~terms "we",~~effectiveness ~~"us",~~of "our", ~~“the~~disclosure ~~Company”,~~controls and ~~"Cannabis~~procedures (as ~~Science"~~defined ~~mean~~in ~~Cannabis~~Rule ~~Science~~13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this report, have concluded ~~Inc.~~that, ~~unless~~based ~~otherwise~~on ~~indicated~~the evaluation of these controls and procedures, that our disclosure controls and procedures were not effective.

~~All~~There were ~~dollar~~no ~~amounts~~changes ~~refer~~in toour ~~U.S.~~internal ~~dollars~~controls ~~unless~~or ~~otherwise~~in other factors during the last fiscal quarter covered by this report that have materially ~~indicated~~affected, or are likely to materially affect the Company’s internal controls over financial reporting.

~~Overview~~PART II OTHER INFORMATION

ITEM ~~Cannabis Science, Inc~~1. (“We” or the “Company”), was incorporated under the laws of the State of Colorado, on February 29, 1996, as Patriot Holdings, Inc. On August 26, 1999, the Company changed its name to National Healthcare Technology, Inc. On June 6, 2007, the Company changed its name from National Healthcare Technology, Inc., to Brighton Oil & Gas, Inc., and converted to a Nevada corporation. On March 25, 2008 the Company changed its name to Gulf Onshore, Inc. On April 6, 2009, the Company changed its name to Cannabis Science, Inc., and obtained a new CUSIP number. BUSINESS

11CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION

OnThis Interim ~~May~~Report 7on Form 10-Q contains forward-looking statements that have been made pursuant to the provisions of Section 27A of the Securities Act of 1933, ~~2009~~Section 21E of the ~~Company~~Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995 and concern matters that involve risks and uncertainties that could cause actual results to differ materially from historical results or from those projected in the forward-looking statements. Discussions containing forward-looking statements may be found in the material set forth under “Business,” “Management’s ~~common~~Discussion and Analysis ~~shares~~of ~~commenced~~Financial ~~trading~~Condition ~~under~~and Results of Operations” and in other sections of this Form 10-Q. Words such as “may,” “will,” “should,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” or similar words are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Although we believe that our opinions and expectations reflected in the ~~new~~forward-looking ~~stock~~statements ~~symbol~~are ~~OTCQB:~~reasonable ~~CBIS~~as of the date of this Report, we cannot guarantee future results, levels of activity, performance or achievements, and our actual results may differ substantially from the views and expectations set forth in this Interim Report on Form 10-Q. We expressly disclaim any intent or obligation to update any forward-looking statements after the date hereof to conform such statements to actual results or to changes in our opinions or expectations.

~~Currently~~Readers should carefully review and consider the various disclosures made by us in this Report, set forth in detail in Part I, under the ~~Company’s~~heading ~~common~~“Risk Factors,” as well as those additional risks described in other documents we file from time to time ~~shares~~with ~~are~~the ~~trading~~Securities ~~under~~and Exchange Commission, which attempt to advise interested parties of the ~~OTC~~risks, ~~Pink~~uncertainties, ~~Sheets~~and ~~market~~other factors ~~with~~that ~~symbol~~affect ~~CBIS~~our business. We undertake no obligation to publicly release the results of any revisions to any forward-looking statements to reflect anticipated or unanticipated events or circumstances occurring after the date of such statements.

~~ITEM~~As used 1Ain this Form 10-Q, the terms "we", "us", "our", “the Company”, and "Cannabis Science" mean Cannabis Science, Inc., ~~RISK~~unless ~~FACTORS~~otherwise indicated.

~~The following discussion of risk factors~~All ~~contains~~dollar ~~forward-looking~~amounts ~~statements.~~refer ~~These risk factors may be important~~ to ~~understanding any statement in this Form 10-Q or elsewhere~~U.S. ~~The~~dollars ~~following~~unless ~~information~~otherwise should be read in conjunction with Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and the consolidated financial statements and related notes in Part II, Item 8, “Financial Statements and Supplementary Data” of this Form 10-Qindicated.

Because of the following factors, as well as other factors affecting the Company’s financial condition and operating results, past financial performance should not be considered to be a reliable indicator of future performance, and investors should not use historical trends to anticipate results or trends in future periods.Overview

~~The~~ Cannabis Science, Inc. (“We” or the “Company”), iswas ~~subject~~incorporated tounder the laws ~~and~~of ~~regulations~~the State of ~~worldwide~~Colorado, ~~changes~~on toFebruary ~~which~~29, ~~could~~1996, ~~hinder~~as Patriot Holdings, Inc. On August 26, 1999, the Company’s ~~medical~~changed ~~cannabis~~its ~~research~~name ~~and~~to ~~increase~~National Healthcare Technology, Inc. On June 6, 2007, the Company’s ~~costs~~changed ~~and~~its name from National Healthcare Technology, Inc., to Brighton Oil & ~~individually~~Gas, orInc., inand converted to a Nevada corporation. On March 25, 2008 the ~~aggregate~~Company ~~adversely~~changed ~~affect~~its name to Gulf Onshore, Inc. On April 6, 2009, the Company’s ~~business~~changed its name to Cannabis Science, Inc., and obtained a new CUSIP number.

~~The Company is subject to laws and regulations~~On ~~affecting~~May ~~its~~7, ~~domestic~~2009 ~~and international operations in medical research and production of medical cannabis. These U.S. and foreign laws and regulations affect~~ the Company’s ~~activities~~common ~~including,~~shares ~~but~~commenced ~~not~~trading ~~limited~~under ~~to,~~the ~~areas~~new ofstock ~~sales~~symbol toOTCQB: only certain legalized regions, labor, advertising, digital content, product label, consumer protection, billing, e-commerce, promotions, quality of services, media, television, intellectual property ownership and infringement, tax, import and export requirements, foreign exchange controls and cash repatriation restrictions, environmental, health, and safetyCBIS.

~~By way of example~~Currently, ~~laws and regulations related~~ ~~to cannabis in United States is listed under Schedule 1 of~~ the ~~Drug~~Company’s ~~Enforcement~~common ~~Administration~~shares ~~(DEA)~~are astrading ~~defined~~ under the ~~United States~~OTC ~~Controlled~~Pink ~~Substances~~Sheets ~~Act~~market ~~even~~with ~~though~~symbol ~~there are 20 states have legalized medical marijuana and eight states legalized for recreational use~~CBIS.

~~Compliance with these laws, regulations and~~Cannabis ~~similar requirements may be onerous and expensive~~Science, ~~and they may be inconsistent from jurisdiction to jurisdiction, further increasing the cost of compliance and doing business~~Inc. ~~Any~~is ~~such~~at ~~costs, which may rise in~~ the ~~future~~forefront ~~as a result~~ of ~~changes~~medical inmarijuana ~~these~~research ~~laws~~ and ~~regulations~~ ordevelopment. The inCompany ~~their~~works ~~interpretation~~with ~~could~~world ~~individually~~authorities on orphytocannabinoid inscience ~~the~~targeting ~~aggregate~~critical ~~make~~illnesses, ~~the~~and ~~Company’s~~adheres ~~products~~to ~~and~~scientific ~~services~~methodologies ~~less attractive~~ to ~~the~~develop, ~~Company’s customers~~produce, ~~delay~~and ~~the~~commercialize phytocannabinoid-based ~~introduction~~pharmaceutical ~~of new~~ products. In ~~in one or more regions~~sum, orwe ~~cause~~are ~~the~~dedicated ~~Company~~ to ~~change~~the orcreation ~~limit~~of ~~its~~cannabis-based ~~business~~medicines, ~~practices.~~both with ~~The Company has implemented policies~~ and ~~procedures~~without ~~designed~~psychoactive properties, to ~~ensure~~treat ~~compliance~~disease ~~with applicable laws~~ and ~~regulations, but there can be no assurance that~~ the ~~Company’s~~symptoms ~~employees,~~of ~~contractors~~disease, oras ~~agents~~well ~~will not~~as ~~violate~~for ~~such~~general ~~laws~~health ~~and regulations or the Company’s policies and procedures~~maintenance.

12ITEM 1A. RISK FACTORS

~~Risk~~The following ~~related~~discussion toof ~~Liquidity~~risk ~~and~~factors ~~Capital~~contains ~~Resources:~~forward-looking ~~Although~~statements. ~~our~~These risk factors may be important to understanding ~~financial~~any ~~statements~~statement ~~have~~in ~~been~~this ~~prepared~~Form on10-Q aor ~~going~~elsewhere. ~~concern~~The ~~basis,~~following weinformation ~~must~~should ~~raise~~be ~~additional~~read ~~capital~~in ~~before~~conjunction ~~September~~with 30Part II, ~~2017~~Item 7, “Management’s toDiscussion and Analysis of Financial Condition and Results of Operations” and the consolidated ~~fund~~financial ~~our~~statements ~~operations~~and related notes in ~~order~~Part toII, ~~continue~~Item 8, as“Financial aStatements ~~going~~and ~~concern~~Supplementary Data” of this Form 10-Q.

~~Turner, Stone & Company, L.L.P., our independent registered~~Because ~~public~~of ~~accounting firm for~~ the ~~fiscal~~following ~~year ended December 31~~factors, ~~2016,~~as ~~has~~well ~~included~~as another ~~explanatory~~factors ~~paragraph~~affecting inthe ~~their~~Company’s ~~opinion that accompanies our audited~~ financial ~~statements~~condition ~~as of~~ and ~~for~~operating ~~the year ended December 31~~results, ~~2016, indicating that our current liquidity~~past ~~position~~financial ~~raises~~performance ~~substantial~~should ~~doubt about our ability to continue as a going concern. If we are unable to improve our liquidity position we may~~ not be ~~able~~considered to ~~continue~~be as a ~~going~~reliable ~~concern.~~indicator ~~The~~of ~~accompany~~future ~~consolidated~~performance, ~~financial~~and ~~statements~~investors doshould not ~~include any adjustments~~use ~~that~~historical ~~might~~trends ~~result if we are unable~~ to ~~continue~~anticipate asresults aor ~~going~~trends ~~concern and, therefore, be required to realize our assets and discharge our liabilities other than~~ in ~~the~~future ~~normal course of business which could cause investors to suffer the loss of all or a substantial portion of their investment~~periods.

~~We anticipate that our principal sources of liquidity will only~~The beCompany ~~sufficient~~is subject to ~~fund~~laws ~~our~~and ~~activities~~regulations ~~needs through September 30~~worldwide, ~~2017.~~changes ~~In order~~ to ~~have~~which ~~sufficient~~could ~~cash~~hinder tothe ~~fund~~Company’s ~~our~~medical ~~operations~~cannabis research ~~beyond~~and ~~September~~increase ~~30,~~the ~~2017,~~Company’s wecosts ~~will~~and ~~need~~individually ~~to raise additional equity~~ or ~~debt capital by September 30, 2017~~ in ~~order~~the toaggregate ~~continue~~adversely ~~as a~~affect ~~going~~the ~~concern~~Company’s ~~and we cannot provide any assurance that we will be successful in doing so~~business.

~~Our~~The Company ~~stockholders~~is ~~are~~ subject to ~~significant~~laws ~~dilution~~and ~~upon~~regulations affecting its domestic and international operations in medical research and production of medical cannabis. These U.S. and foreign laws and regulations affect the ~~occurrence~~Company’s activities including, but not limited to, areas of sales to only certain ~~events~~legalized ~~which~~regions, ~~could~~labor, ~~result~~advertising, indigital acontent, ~~decrease~~product inlabel, ~~our~~consumer ~~stock~~protection, billing, ~~price.~~e-commerce, promotions, quality of services, media, television, intellectual property ownership and infringement, tax, import and export requirements, foreign exchange controls and cash repatriation restrictions, environmental, health, and safety.

AsBy way of ~~December 31~~example, ~~2016,~~laws weand ~~had~~regulations ~~approximately~~related ~~1.53~~to ~~billion shares~~cannabis ofin ~~our~~United ~~common~~States ~~stock~~is ~~reserved~~listed orunder ~~designated~~Schedule ~~for~~1 ~~future issuance upon conversion~~ of ~~outstanding~~the ~~convertible~~Drug ~~promissory~~Enforcement ~~notes.~~Administration ~~Further,~~(DEA) weas ~~may~~defined ~~from~~under ~~time~~the toUnited ~~time~~States ~~make~~Controlled anSubstances ~~offer~~Act toeven ~~our~~though ~~debtors~~there orare ~~consultants~~20 tostates ~~exchange their outstanding debts or services for shares of our common stock. Any future issuance of common shares will~~ have alegalized ~~further~~medical ~~dilutive effect on our existing stockholders~~marijuana and ~~could~~eight ~~result~~states inlegalized afor ~~decrease~~recreational ~~in our stock prices~~use.

~~Investment in new business strategies and acquisitions could disrupt the Company’s ongoing business and present risks not originally contemplated.~~12

~~The~~Compliance with ~~Company~~these ~~has~~laws, ~~invested~~regulations and similar requirements may be onerous and expensive, and inthey may be inconsistent from jurisdiction to jurisdiction, further increasing the ~~future~~cost ~~may~~of ~~invest~~compliance and doing business. Any such costs, which may rise in ~~new~~the ~~business~~future ~~strategies~~as a result of changes in these laws and regulations or ~~acquisitions.~~in ~~Such~~their ~~endeavors~~interpretation ~~may~~could ~~involve~~individually ~~significant~~or ~~risks~~in ~~and~~the aggregate make the Company’s ~~uncertainties~~products and services less attractive to the Company’s customers, ~~including~~delay ~~distraction~~the introduction of ~~management~~new ~~from~~products ~~current~~in ~~operations~~one or more regions, ~~greater~~or ~~than~~cause ~~expected~~the ~~liabilities~~Company to change or limit its business practices. The Company has implemented policies and ~~expenses,~~procedures designed ~~inadequate~~to ~~return~~ensure ofcompliance ~~capital,~~with applicable laws and ~~unidentified~~regulations, ~~issues~~but ~~not~~there ~~discovered~~can inbe no assurance that the Company’s ~~due~~employees, ~~diligence.~~contractors, or ~~These~~agents ~~new~~will ~~ventures are~~not ~~inherently~~violate ~~risky~~such laws and ~~may~~regulations ~~not~~or bethe ~~successful~~Company’s policies and procedures.

~~The~~Risk related ~~Company’s~~to ~~stock~~Liquidity ~~price~~and isCapital ~~subject~~Resources: Although our financial statements have been prepared on a going concern basis, we must raise additional capital before September 30, 2017 to ~~volatility~~fund our operations in order to continue as a going concern.

~~The~~Turner, Stone & Company’s, ~~stock~~L.L.P., ~~continues to~~our ~~experience~~independent ~~substantial~~registered ~~price~~public ~~volatility.~~accounting ~~Additionally,~~firm for the ~~Company,~~fiscal ~~the~~year ~~medical~~ended ~~cannabis~~December ~~industry~~31, 2016, has included an explanatory paragraph in their opinion that accompanies our audited financial statements as of and for the ~~stock~~year ~~market~~ended December 31, 2016, indicating that our current liquidity position raises substantial doubt about our ability to continue as a ~~whole~~going ~~have~~concern. ~~experienced~~If ~~extreme~~we ~~stock~~are ~~price~~unable ~~and~~to ~~volume~~improve ~~fluctuations~~our liquidity position we may not be able to continue as a going concern. The accompany consolidated financial statements do not include any adjustments that ~~have~~might ~~affected~~result ~~stock~~if ~~prices~~we are unable to continue as a going concern and, therefore, be required to realize our assets and discharge our liabilities other than in ~~ways~~the ~~that~~normal ~~may~~course ~~have~~of ~~been~~business ~~unrelated~~which could cause investors to ~~these~~suffer ~~companies’~~the ~~operating~~loss ~~performance~~of all or a substantial portion of their investment.

~~The~~We anticipate ~~Company’s~~that ~~ability~~our principal sources of liquidity will only be sufficient to ~~raise~~fund ~~additional~~our ~~capital~~activities needs through September 30, 2017. In order to have sufficient cash to fund our operations beyond September 30, 2017, we will need to raise additional equity or debt capital by September 30, 2017 in order to continue as a going concern and we cannot provide any assurance that we will be successful in doing so.

~~The Company is required to raise additional~~Our ~~funds~~stockholders toare ~~acquire~~subject ~~research and growing facilities, and~~ to ~~cover~~significant ~~cost~~dilution ofupon ~~operations.~~the Weoccurrence ~~intend to do so through additional public or private offerings~~ of ~~debt~~certain orevents ~~equity~~which ~~securities.~~could ~~There~~result ~~are~~in noa ~~commitment~~decrease ~~or arrangements for other offerings~~ in ~~place, no guaranties~~our ~~that~~stock ~~any such financings would be forthcoming or as to the terms of any such financings~~price.

~~ITEM~~As of 2June 30, 2017, we had approximately 1.906 ~~LEGAL~~billion ~~PROCEEDINGS~~shares of our common stock reserved or designated for future issuance upon conversion of outstanding convertible promissory notes. Further, we may from time to time make an offer to our debtors or consultants to exchange their outstanding debts or services for shares of our common stock. Any future issuance of common shares will have a further dilutive effect on our existing stockholders and could result in a decrease in our stock prices.

~~None~~Investment in new business strategies and acquisitions could disrupt the Company’s ongoing business and present risks not originally contemplated.

13The Company has invested, and in the future may invest, in new business strategies or acquisitions. Such endeavors may involve significant risks and uncertainties, including distraction of management from current operations, greater than expected liabilities and expenses, inadequate return of capital, and unidentified issues not discovered in the Company’s due diligence. These new ventures are inherently risky and may not be successful.

~~ITEM~~The Company’s 3.stock ~~UNREGISTERED~~price ~~SALES~~is OFsubject ~~EQUITY~~to ~~SECURITIES AND USE OF PROCEEDS~~volatility.

~~During~~The Company’s ~~the~~stock ~~three~~continues ~~months~~to ~~ended~~experience ~~March 31~~substantial price volatility. Additionally, ~~2017~~the Company, wethe medical cannabis industry, and the stock market as a whole have ~~issued~~experienced ~~securities~~extreme ~~using~~stock ~~exemptions~~price ~~available~~and ~~under~~volume ~~the~~fluctuations ~~Securities~~that ~~Act~~have ofaffected ~~1933:~~stock prices in ways that may have been unrelated to these companies’ operating performance.

AsThe Company’s ~~set~~ability ~~out~~to ~~below,~~raise weadditional ~~have~~capital ~~issued~~to ~~securities~~fund ~~in exchange for services:~~operations

OnThe Company ~~February~~is ~~16,~~required ~~2017,~~to ~~the~~raise ~~Company~~additional ~~issued 5~~funds to acquire research and growing facilities,~~000,000~~ ~~shares~~and ofto ~~R144~~cover ~~restricted~~cost ~~common~~of ~~stock~~operations. We intend to ado ~~consultant~~so ~~with~~through aadditional ~~fair~~public ~~market~~or ~~value~~private offerings of ~~$350,000~~debt ~~for~~or ~~legal~~equity ~~and~~securities. ~~general~~There ~~consulting services~~are ~~under~~no acommitment ~~consulting~~or ~~agreement~~arrangements for ~~dated~~other ~~January~~offerings 13in place, ~~2017~~no guaranties that any such financings would be forthcoming or as to the terms of any such financings.

On February 16, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock to a consultant with a fair market value of $700,000 for legal and general consulting services under a consulting agreement dated January 13~~, 2017.~~

~~On February 16, 2017, the Company issued~~ITEM ~~10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0~~2.05 LEGAL ~~and a fair market value of $700,000 to a consultant under a consulting agreement dated January 13, 2017.~~PROCEEDINGS

~~On February 28, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0~~None.~~04 and a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH under an Option Agreement dated January 24, 2017.~~

~~On March 2, 2017, the Company issued~~ ITEM 3~~,000,000~~. UNREGISTERED ~~shares~~SALES ~~of R144~~OF ~~restricted~~EQUITY ~~common~~SECURITIES ~~stock~~AND toUSE aOF ~~consultant with a fair market value of $238,500 for consulting services under a consulting agreement dated March 2, 2017.~~PROCEEDS

OnDuring the ~~March~~six 7months ended June 30, 2017, ~~the~~we ~~Company~~have issued ~~15,000,000~~securities ~~shares~~using ~~S-8 registered~~exemptions ~~free~~available ~~trading common stock~~ under the ~~2016~~Securities ~~Equity~~Act ~~Award Plan B with a fair market value~~ of ~~$1,270,500 for consulting services under a consulting agreement dated March 7, 2017.~~1933:

OnAs set ~~March~~out 13below, ~~2017,~~we ~~the~~have ~~Company~~ issued ~~10,000,000~~securities ~~shares~~in ~~S-8 registered~~exchange ~~free trading common stock under the 2016 Equity Award Plan B with a fair market value of $883,000~~ for ~~consulting~~ services ~~under a consulting agreement dated July 6 2016.~~:

On February ~~March 13~~16, 2017, the Company issued 155,000,000 shares ~~S-8 registered~~of ~~free~~R144 ~~trading~~restricted common stock ~~under~~to ~~the~~a ~~2016~~consultant ~~Equity Award Plan B~~ with a fair market value of $1350,~~324,500~~000 for legal and general consulting services under a consulting agreement dated ~~April~~January 2913, ~~2015~~2017.

On February ~~March 27~~16, 2017, the Company issued 1510,000,000 shares S-8 registered free-trading common stock ~~under~~to ana ~~Option~~consultant ~~Agreement of 2016 Equity Award Plan B~~ with ~~exercise price at $0.075 and~~ a fair market value of $1700,~~140,~~000 tofor alegal ~~consultant~~and general consulting services under ana ~~Option~~consulting ~~Agreement~~agreement dated ~~March~~January 2713, 2017.

~~ITEM~~On February 416, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.05 ~~DEFAULTS~~and ~~UPON~~a ~~SENIOR~~fair ~~SECURITIES~~market value of $700,000 to a consultant under a consulting agreement dated January 13, 2017.

~~None~~On February 28, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.04 and a fair market value of $815,000 to Alfredo Dupetit-Bernardi, President/CEO of Cannabis Science Europe GmbH under an Option Agreement dated January 24, 2017.

~~ITEM~~On March 5.2, ~~MINE~~2017, ~~SAFETY~~the ~~DISCLOSURES~~Company issued 3,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $238,500 for consulting services under a consulting agreement dated March 2, 2017.

~~N/A~~On March 7, 2017, the Company issued 15,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $1,270,500 for consulting services under a consulting agreement dated March 7, 2017.

~~ITEM~~On March 6.13, ~~OTHER~~2017, ~~INFORMATION~~the Company issued 10,000,000 shares S-8 registered free trading common stock under the 2016 Equity Award Plan B with a fair market value of $883,000 for consulting services under a consulting agreement dated July 6 2016.

~~See~~On March ~~Financial~~13, ~~Statement~~2017, ~~Notes~~the 4Company inissued ~~regards~~15,000,000 toshares S-8 registered free trading common stock ~~compensation~~under the 2016 Equity Award Plan B with a fair market value of $1,324,500 for ~~officers~~consulting ~~and~~services ~~directors~~under a consulting agreement dated April 29, 2015.

14On March 27, 2017, the Company issued 15,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.075 and a fair market value of $1,140,000 to a consultant under an Option Agreement dated March 27, 2017.

~~ITEM~~On April 718, 2017, the Company issued 10,000,000 shares S-8 registered free-trading common stock under an Option Agreement of 2016 Equity Award Plan B with exercise price at $0.02 ~~EXHIBITS~~and a fair market value of $829,000 to Chief Medical Officer, Dr. Allen Herman.

Exhibit No.	Document Description	Filed Herewith (X) Incorporated by ref (I)
31.1	Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
31.2	Certification by Benjamin Tam, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
99.1	Promissory Notes	X
EX-101.INS	XBRL Instance Document	X
EX-101.SCH	XBRL Taxonomy Extension Schema	X
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase	X
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase	X

On May 5, 2017, the Company issued 7,000,000 shares of R144 restricted common stock to a consultant with a fair market value of $469,000 for consulting services pursuant to a one year consulting agreement.

15On May 17, 2017, the Company issued 1,500,000 shares of R144 restricted common stock to a consultant with a fair market value of $93,000 for consulting services pursuant to a three-month Marketing agreement.

~~SIGNATURES~~14

~~Pursuant to the requirements of the Securities Exchange Act~~ITEM of4. DEFAULTS ~~1934,~~UPON ~~the~~SENIOR ~~registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.~~SECURITIES

	CANNABIS SCIENCE INC.
Date: August 10, 2017	/s/ Raymond C. Dabney
		Raymond C. Dabney
		Chief Executive Officer
Date: August 10, 2017	/s/ Benjamin Tam
		Benjamin Tam
		Chief Financial Officer

None.

16ITEM 5. MINE SAFETY DISCLOSURES

N/A

ITEM 6. OTHER INFORMATION

See Financial Statement Notes 4 in regards to stock compensation for officers and directors.

ITEM 7. EXHIBITS

Exhibit No.	Document Description	Filed Herewith (X) Incorporated by ref (I)

31.1	Certification by Raymond C. Dabney, Chief Executive Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
31.2	Certification by Benjamin Tam, Chief Financial Officer, as required under Section 302 of Sarbanes-Oxley Act of 2002.	X
32.1	Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
32.2	Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	X
99.1	Promissory Notes	X
EX-101.INS	XBRL Instance Document	X
EX-101.SCH	XBRL Taxonomy Extension Schema	X
EX-101.CAL	XBRL Taxonomy Extension Calculation Linkbase	X
EX-101.LAB	XBRL Taxonomy Extension Label Linkbase	X
EX-101.PRE	XBRL Taxonomy Extension Presentation Linkbase	X
EX-101.DEF	XBRL Taxonomy Extension Definition Linkbase	X

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


	CANNABIS SCIENCE INC.


Date: August 23, 2017	/s/ Raymond C. Dabney
		Raymond C. Dabney
		Chief Executive Officer


Date: August 23, 2017	/s/ Benjamin Tam
		Benjamin Tam
		Chief Financial Officer

Filing Compare · CANNABIS SCIENCE, INC.